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Clonal deconvolution of transcriptomic signatures and their
spatial organisation in a mouse model of breast cancer
Sophia Alisa Wild
Intratumour heterogeneity is a phenomenon during cancer progression in which
cancer cells diverge and form clonal populations with distinct phenotypic, genetic, or
epigenetic states within the same tumour. This intrinsic heterogeneity provides a fuel
for cancer evolution enabling tumour cell populations to adapt to selective pressures
imposed by the tumour microenvironment or therapeutic interventions. Lineage-tracing
approaches shed light into the clonal dynamics of complex populations, but generally
lack the ability to directly associate clonal lineage with measurements that infer phe-
notype such as epigenetics and transcriptomics. In contrast, single-cell sequencing
techniques can provide insight into the makeup of complex biological ecosystems, re-
vealing the presence of rare cell populations that are typically masked in bulk analyses,
but lack the ability to link these cell populations to clonal lineages.
To address this challenge, we developed the WILDseq platform, a novel approach
that allows clonal characterisation at the single-cell transcriptomic level while facilitat-
ing the prospective analysis of dynamic regulation of phenotypic heterogeneity under
the selective pressure of therapeutic intervention. WILDseq relies on uniquely labelling
individual cells with a heritable, expressed DNA barcode coupled with high-throughput
single-cell RNA-sequencing. Importantly, this lentiviral-labelling approach can be
deployed in any model system that is susceptible to viral transfection. Thus, this
platform allows the comprehensive and systematic characterisation of clonal phenotypic
di erences within complex populations.
Here we demonstrate how this technology can be used to determine clonal popula-
tions which are sensitive or resistant to a particular therapeutic intervention, identify
transcriptomic signatures that correlate with these phenotypes and analyse how these
cells adapt their transcriptomes to escape therapy. We have applied WILDseq to
the study of di erential clonal responses to chemotherapy in the heterogeneous 4T1
model of breast cancer and validated transcriptomic signatures of therapeutic resistance
and sensitivity in primary patient data. We additionally used WILDseq to study the
clonal response to the epigenetic regulator JQ1 which revealed intrinsic signatures
that primed clones to JQ1 sensitivity. We observed JQ1-dependent depletion of CD8+
cytotoxic T-cells and suggest that this drives changes in clonal distribution. Finally,
we are working on developing a high throughput FISH assay to leverage the WILDseq
technology for mapping clonal and transcriptional identities spatially.
Collectively, this thesis contributes to the characterisation and understanding of
breast cancer heterogeneity and the impact of clonal architecture on tumour progression
and response to therapy.
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Most human tumours are composed of genetically and phenotypically heterogeneous
cancer cell populations that evolve dynamically in space and time following principles
of Darwinian evolution. This extensive genetic and phenotypic diversity exists not only
between patient tumours (intertumoural heterogeneity), but also within individual
tumours (intratumoural heterogeneity) (Figure 1.1). Intratumour heterogeneity is
a key driver of cancer progression underpinning important emergent features such
as drug resistance and metastasis and thus, poses a major clinical challenge. The
origins and dynamics of tumour heterogeneity are still poorly understood and di erent
underlying mechanisms have been proposed, including cell-autonomous (e.g. genetic
and epigenetic) and non-cell-autonomous (e.g. tumour microenvironment) as well as
stochastic events.
Intratumour heterogeneity can manifest in a spatial manner, describing the varying
distribution of a heterogeneous cell population within the primary site or across di er-
ent disease sites, while temporal heterogeneity illustrates the dynamic variation of the
tumour cell population over time.
2 Introduction
Figure 1.1 Tumour heterogeneity. Tumour heterogeneity can be classified into intertu-
moural heterogeneity, describing the variations in the molecular makeup of tumours between
patients, and intratumoural heterogeneity which can be observed within individual tumours.
Intratumoural heterogeneity can either occur between di erent geographical regions of a
tumour (spatial) or as molecular evolution of tumours over time (temporal). Inter- as well as
intratumoural heterogeneity can complicate diagnosis and challenge therapeutic approaches.
Unravelling tumor heterogeneity has a major clinical impact, as intratumour hetero-
geneity is a mechanism of therapeutic resistance. The evolution of resistant subpopula-
tions and cellular changes in phenotypes largely a ects therapeutic outcome. However,
intratumour heterogeneity still remains poorly characterized across cancer types. Sev-
eral studies have revealed the presence of genetic heterogeneity, the most studied aspect
of intratumour heterogeneity, using whole-exome multiregion spatial sequencing or
next-generation sequencing mutational profiling (Gerlinger et al., 2012; Shah et al.,
2012). In an e ort to characterise genetic intratumour heterogeneity in multiple cancer
types, the Pan-Cancer Analysis of Whole Genomes (PCAWG) Consortium identified
the presence of rich subclonal architectures with linear and branching evolutionary
paths as well as transcriptomic alteration signatures which were associated with DNA
mutational signatures (Calabrese et al., 2020; Gerstung et al., 2020).
1.1.1 Breast cancer tumour heterogeneity
Breast cancer is the most frequently diagnosed cancer and is the second most lethal
cancer in women worldwide after lung cancer. Breast cancer comprises a heterogeneous
group of distinct subtypes characterised by their genomic, phenotypic and biological
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features. Based on the presence of clinical and pathological features, including estrogen
and progesterone receptors (ER and PR), and HER2, tumours are classified into ER+,
HER2+, and ER≠PR≠HER2≠ (triple-negative) subtypes.
Early transcriptomic profiling using microarrays classified breast cancer tumours
into four major intrinsic subtypes (luminal-A, luminal-B, basal-like, and HER2-enriched)
and a normal breast-like group that showed significant di erences in clinical outcome,
incidence and therapy response (Carey et al., 2006; Perou et al., 2000; Sørlie et al.,
2001). Molecular characterisation of intrinsic subtypes using the PAM50 score based on
the expression of 50 genes, further refined classification of patients into these prognostic
groups and allowed prediction of risk of recurrence and treatment response (Nielsen
et al., 2010; Parker et al., 2009; Perou et al., 2000). Additional gene-expression analysis
further revealed another intrinsic subtype referred to as claudin-low (Prat et al., 2010).
More recently, genomic and transcriptomic analysis of over 2,000 breast tumours
has been used to stratify breast tumours into 11 di erent integrative cluster (IntClust).
Each cluster has a distinct pattern of copy number aberrations (CNAs) and gene
expression changes. The integrative subtypes each show di erences in prognostic values
and/or predictive value (Curtis et al., 2012; Nielsen et al., 2010; Pereira et al., 2016;
The Cancer Genome Atlas Network, 2012).
Previous work in triple-negative breast cancer (TNBC) patients have shown high
levels of somatic mutations, frequent mutations in TP53, and complex genomic rear-
rangements revealing the presence of extensive intratumour heterogeneity (Gao et al.,
2016; Navin et al., 2011; Shah et al., 2012; Wang et al., 2014). Sequencing of TNBC
and ER+ breast cancer has suggested that breast tumours have the ability to undergo
major shifts in genomic aberrations upon neoadjuvant therapy (Kim et al., 2018; Yates
et al., 2015). Kim et al. further showed that while the genotypes were pre-existing
and adaptively selected in TNBC patients, transcriptional reprogramming was induced
upon treatment (Kim et al., 2018). In a more recent study, Saheli et al. generated
single-cell whole-genome sequencing from one HER2+ and three TNBC patient-derived
xenografts (PDX) (Salehi et al., 2021). Notably, phylogenetic analysis revealed up
to eleven major clones in the TNBC PDXs, while only four clones were observed
in the HER2+ subtype. Drug treatment of TNBC PDXs resulted in a change of
clonal dynamics with cisplatin-resistant clones emerging. Based on the findings of
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Caswell-Jin et al. breast tumours seem to have a higher and more widely variable
level of intratumour heterogeneity in untreated as well as treated tumours compared to
other cancer types, such as colon, lung or esophagus cancer (Caswell-Jin et al., 2019).
The high level of intratumour heterogeneity could be explained through several factors,
including high selective pressure during primary tumour growth, di erences in the
microenvironment, spatial boundaries within the tumour, or di erent growth modes.
Thus, it is of highest priority to gain a better understanding of clonal diversity in
breast tumours as this might be critical indicator to how tumour cells will encounter
various selective pressures.
1.1.2 The 4T1 mouse model
The murine mammary cancer cell line 4T1 is a syngenic mammary carcinoma model for
breast cancer and in particular TNBC. This cell line was originally derived from a single
spontaneously arising mammary tumour (410.4 tumour) of a mouse mammary tumor
virus (MMTV) positive BALB/c mouse foster nursed on a C3H mother (BALB/BfC3H)
(Heppner et al., 1978). The 4T1 line was selected from the 410.4 tumour through
its 6-thioguanine-resistance without mutagen treatment (Aslakson and Miller, 1992).
Injection of a 4T1 cell suspension into the mammary fat-pad results in the formation of
4T1 tumours which are highly tumourigenic, invasive with the ability to spontaneously
metastasize from the primary tumour to multiple distant sites, including lymph nodes,
blood, lung, brain, and bone (Lelekakis et al., 1999; Pulaski and Ostrand-Rosenberg,
1998).
Based on the lack of of ER, PgR, and ErbB2 expression, 4T1 is widely used as a
model for TNBC and closely resembles the clinical course of the disease in patients,
including the location of the primary tumour and its metastastic spread (Schroers
et al., 2020).
Using the 4T1 cell line, the Hannon laboratory has developed a functional model of
breast cancer heterogeneity capable of identifying di erent critical phenotypical drivers
in a mixed population. Wagenblast et al. created a polyclonal population of 4T1 cells
by single-cell sorting 4T1 cells labelled with a high-complexity DNA barcode library
and mixing 23 clonal lines at equal ratios for tumour formation. The di erent subclones
varied in their abilities to dominate the primary tumour or spontaneously metasta-
size to distant organs implicating the presence of clones with diverse transcriptomic
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and phenotypic traits in a relative small subpopulation of cells (Wagenblast et al., 2015).
1.1.3 Tumour heterogeneity as an obstacle for therapeutic
response
Therapeutic resistance continues to be a major clinical obstacle. Resistance to treatment
can be classified as intrinsic (primary), manifested by the lack of a clinical response
following therapy, or acquired (secondary), representing local or distant recurrence
following initial response to therapy (Marine et al., 2020). At a cellular level, intrinsic
resistance occurs due to resistance-mediating factors pre-existing in the bulk of tumour
cells making therapy ine ective, whereas in acquired resistance, tumours show a
dramatic initial response in most cases, but eventually develop resistance during
treatment over time (Burrell and Swanton, 2014; Holohan et al., 2013). Acquired
resistance can arise either through genetic evolution by the acquisition of de novo
mutations or non-genetic mechanisms, including epigenetic and phenotypic changes,
allowing cancer cells to adapt to the selective pressure. With tumours being dynamically
evolving entities, intratumour heterogeneity has been recognized as a substantial source
of poor prognosis and therapy resistance (Andor et al., 2016; Bhang et al., 2015;
Das Thakur et al., 2013; Jamal-Hanjani et al., 2017; Juric et al., 2015; Zhang et al.,
2014). Cancer therapy constitutes a strong, directional selection pressure that shapes
the tumour evolutionary landscape (Figure 1.2) (Almendro et al., 2014). Most patients
with advanced or metastatic disease experience therapeutic resistance leaving residual
cancer cells behind, traditionally called "minimal residual disease" (MRD), and thus
providing a reservoir for local or distant disease relapse. While genetic evolution was
conceptually the driving force of acquired resistance, there is growing evidence that
it is unlikely to be the main mechanism for therapeutic evasion (Marine et al., 2020).
Notably, drug resistance can arise in a minor pre-existing subpopulation either through
therapy-induced selection of cells which are intrinsically highly resistant to treatment
or through an adaptive response, such as rewiring of signalling pathways or phenotypic
switch (Holohan et al., 2013). In both cases, tumour heterogeneity poses a major
problem substantially fuelling drug resistance.
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Figure 1.2 Tumour evolution and emergence of therapy resistance through non-
genetic mechanisms. Clonal evolution is a key feature of cancer progression enabling
tumour cell populations to adapt to selective pressures. When challenged with therapy, the
bulk of clones are eradicated, whereas others confer a clonal advantage under therapeutic
pressure. Cancer relapse is driven by a rare subpopulation of clones that are able to survive
the initial therapeutic challenge. Adapted from Marine et al. (2020).
Despite treatment induced changes in the clonal composition of tumours, rela-
tively few studies have been done in tumours, with the exception of hematopoietic
malignancies (Ding et al., 2010; Landau et al., 2013). Using WGS/WES, studies in
hematopoietic cancers compared diagnostic and relapse samples of leukemia patients.
Ding et al. discovered either a new mutation in the original founding clone at relapse, or
the expansion of a subclone of the founding clone with additional mutations (Ding et al.,
2012). Moreover, Landau et al. found that ten out of 12 treated patients underwent
clonal evolution, in contrast to one patient of the six untreated cases. Interestingly,
they observed an enrichment of subclonal driver mutations with treatment and an
increase in subclonal complexity suggesting a selection process for more aggressive
clones during treatment (Landau et al., 2013).
A study by Kurtova et al. in bladder cancer linked resistance to treatment with
cytotoxic chemotherapy to the selection of a pre-existing subpopulation (Kurtova et al.,
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2015). Another study in breast cancer patients treated with chemotherapy suggested
no change in genetic diversity, but instead an upregulation of EMT-associated genes
and a selection for mesenchymal phenotypes (Almendro et al., 2014; Li et al., 2008).
This is in line with the long standing concept of a treatment-induced phenotype-switch
from epithelial to mesenchymal (Marine et al., 2020). Whereas most of these studies
were relying on targeted markers or bulk genomic sequencing with limited resolution
of clonal evolution, Kim et al. used a combined approach of single-cell DNA- and
RNA-sequencing to analyse biopsies of TNBC patients before and after treatment.
Their results revealed that resistant genotypes were pre-existing and adaptively selected
in response to chemotherapy (Kim et al., 2018). Nevertheless, our understanding of how
treatment impacts intratumour heterogeneity or how tumour heterogeneity impacts
treatment which then in turn plays into the e ectiveness of treatment, is still very
sparse.
1.2 Single-cell RNA sequencing technologies
Single-cell RNA sequencing (scRNA-seq) has emerged as an essential tool for study-
ing heterogeneous cell populations, including characterization of cell states, lineages
and circuits. Since the first single-cell transcriptome sequencing was published in
2009, various new techniques have been developed (Tang et al., 2009). Methods
for scRNA-seq use di erent strategies to barcode transcripts for their cell of origin
and generate sequencing libraries. Low-throughput methods rely on time-consuming
fluorescence-activated cell sorting (FACS) of cells into many plates that must be pro-
cessed separately (Hashimshony et al., 2016; Picelli et al., 2013). High-throughput
approaches encapsulate single cells in droplets (Klein et al., 2015; Macosko et al.,
2015; Zheng et al., 2017) or wells (Gierahn et al., 2017) containing reagents and
barcoded beads. By using a scalable, combinatorial indexing strategy, all mRNA in
a droplet or well is assigned to their cell of origin without physically isolating single cells.
Currently, there are three droplet-based systems for scRNA-seq: inDrop (Klein
et al., 2015), Drop-seq (Macosko et al., 2015) and 10X Genomics Chromium (10X)
(Zheng et al., 2017). All of these technologies share similar workflows, including droplet
generation and barcoded oligonucleotide coated beads, but di er in the bead and
barcode design as well as their cDNA amplification method (Zhang et al., 2019). In
a comparative study 10X generally performed with higher molecular sensitivity and
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precision and less technical noise, while o ering a user-friendly platform (Zhang et al.,
2019).
Figure 1.3 10X Genomics Platform. Single cells are combined with reagents and en-
capsulated in GEMs containing barcoded gel beads. Gel beads are coated with barcoded
oligonucleotides consisting of Illumina adapters, 10X barcode (cell barcode), UMIs and oligo
dTs, which capture polyadenylated RNAs. RT reaction takes place inside each GEM, followed
by pooling of barcoded cDNA for amplification and library preparation in bulk.
The 10X Genomics technology relies on capturing single cells on a microfluidic
platform (Figure 1.3). Specifically, single cells are partitioned in Gel Beads in Emulsion
(GEM) which further contain barcoded oligonucleotide primers and reagents for reverse
transcription (RT) reactions. Each primer contains a poly(dT) sequence to capture
mRNAs, a 12 nucleotide (nt) unique molecular identifier (UMI) to count individual
mRNA molecules, a 16 nt 10x barcode unique to each cell and an Illumina TruSeq
Read 1 primer binding site. Following GEM generation, cells are lysed, polyadenylated
mRNA is captured by the poly(dT) part of the primer and reverse transcribed. All
cDNA from single cells has been assigned with the same 10X barcode, allowing to
map sequencing reads back to the single cell of origin. Thus, library preparation is
performed in a bulk reaction followed by Illumina sequencing.
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1.3 Lineage tracing strategies
Unravelling molecular dynamics, cell-fate decisions and spatial organisation of cells is
the fundamental goal for understanding normal tissue development and homeostasis
as well as disease. During di erentiation, stem and progenitor cells move along a
trajectory of cell fate decisions, refining their identity and function until reaching a
terminal state or become quiescent until further di erentiation occurs later in life. The
gold standard for reconstructing the hierarchic relationship between an individual cell
and its clonal descendants is lineage tracing, in which an individual cell is labelled
with a heritable marker at an early time point in order to profile the fate of its clonal
progeny at a later time point (Jensen and Dymecki, 2014). Pioneered in the 19th
century, lineage tracing represents an essential tool for understanding mechanisms and
dynamics of stem and progenitor cell fate determination. These cell fate determinations
are associated with changes in the transcriptional and epigentic landscape of cell states.
The same principles can be applied to cancer progression which also underlies
an evolutionary process leaving phylogenetic traces along the route from the early
transformation of normal cells into malignant cells to forming metastases at distant
sites and adapting to environmental pressure through drugs or e ects of the immune
system (Schwartz and Schä er, 2017).
Traditionally reliant on microscopy, prospective lineage tracing approaches have
evolved to using heritable markers, including fluorescent proteins (Barker et al., 2007),
mobile transposable elements (Sun et al., 2014), viral DNA barcodes (Naik et al., 2013)
and Cre-mediated tissue-specific recombination (Pei et al., 2017), that were introduced
into a cell and used for tracking its descendants. In contrast, retrospective lineage
tracing utilises endogenous markers that naturally accumulate in the genome, such as
somatic mutations (Ju et al., 2017; Zafar et al., 2017), microsatellite repeats (Frumkin
et al., 2005) or epigenetic markers (Mooijman et al., 2016). Although valuable insights
were gathered using these techniques, they cannot link the lineage information to
a functional phenotype and are often limited by the number of cells and markers
(Woodworth et al., 2017).
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1.3.1 Lineage tracing by barcode-sequencing
Parallel advances in next-generation sequencing have opened up a new generation of
genetic lineage tracing approaches (Figure 1.4). While the number of clones that
can be tracked with fluorescent reporters is intrinsically limited, the complexity of
DNA sequence barcodes scales exponentially with the length and multiplicity of the
barcodes (Wagner and Klein, 2020). Each founder cell contains a unique DNA barcode,
meaning the descendants of each founder cell inherit the barcode and can therefore be
distinguished as a clonal unit.
In the beginning, the use of DNA barcodes relied on the identification of unique
retroviral integration sites combined with Southern blot or PCR assays to read the
barcode identity (Keller et al., 1985; Lemischka et al., 1986). Over the last few years,
viral barcoding has been extensively used to delineate how hematopoietic stem and
progenitor cells (HSPCs) di erentiate and comprise blood (Gerlach et al., 2013; Gerrits
et al., 2010; Lu et al., 2011; Naik et al., 2013). Moreover, Nguyen et al. used viral
barcoding to reveal the highly complex clonal growth dynamics in serially xenograft
transplantations (Nguyen et al., 2014).
Another recently developed technology relies on CRISPR-Cas9-directed genome
editing to generate high-diversity DNA barcodes over time. The barcode, an array of
clustered, regularly interspaced short palindromic repeats (CRISPR)/Cas9 target sites,
is targeted by Cas9 resulting in a stable insertion or deletion (indel) "allele" that is
inherited over subsequent generations. As cells divide, they acquire more Cas9-induced
mutations at additional sites enabling the further deciphering of phylogenetic clades of
cells. The first methods to demonstrate this principle were homing CRISPR (Kalhor
et al., 2018, 2017) and genome editing of synthetic target arrays for lineage tracing
(GESTALT) (McKenna et al., 2016). As an alternative to CRISPR-Cas9-based methods,
Pei et al. used a Cre-loxP recombination system, termed Polylox, for endogenous
barcoding of a mouse model (Pei et al., 2017, 2019). The Polylox barcode cassette
consists of ten loxP sites in alternating orientations and nine intervening DNA that
can be inverted or excised by Cre recombinase depending on the orientation of the
flanking LoxP sites. By breeding the Polylox mouse model with a tissue-specific and
inducible Cre mouse models, labeling of unique clones in a tissue and time-specific
manner is achieved (Pei et al., 2019).
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Figure 1.4 Prospective lineage tracing approaches. a | Viral barcoding systems rely
on integration of a reporter transgene and a DNA barcode into the genome of the host cell.
After propagation to progeny, all descendants from one founder cell share the same barcode,
while clonally unrelated cells have di erent barcodes. Lineage tracing starts at the point
of infection. b | Instead of using a viral system, barcodes can also be integrated into the
genome using a transposon based system. c | Genome-editing systems use a lineage barcode
with a CRISPR target array that accumulates mutations over time. Similar to retrospective
approaches, phylogenetic trees are reconstructed based on the mutational patterns shared
between cells. d | Genetic recombination systems, such as Cre-loxP, rely on the expression of
a recombinase, controlled by a tissue-specific or cell-specific promoter. Upon Cre activation
all progeny will be labeled with the reporter. Adapted from Woodworth et al. (2017).
1.3.2 Retrospective approaches
Prospective lineage tracing approaches rely on the introduction of exogenous markers
into cells which marks the starting point and allows tracking of clones. However, such
manipulation is not possible in the context of human development and disease. To
overcome these limitations, endogenous markers, including single nucleotide variations
(SNVs), copy number variations (CNVs), or other inheritable elements that accumulate
over time can be used for lineage tracing. Similar to genetic barcodes, mutational marks
are passed on to all progeny of the mutated founder cell. Due to the low frequency of
naturally occurring mutations, high sequencing coverage is required.
CNVs are classified as DNA sequences more than 1 kb long present in various copy
numbers when compared to the reference genome. Due to their relative ease of detection
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in single-cell sequencing data, CNVs represent a potentially useful lineage-tracing tool.
Several human diseases, especially cancer, have been linked to CNVs, and there has
been evidence of the presence of CNVs also in healthy tissues, including the brain
and skin (Abyzov et al., 2012; Cai et al., 2014; McConnell et al., 2013; Zarrei et al.,
2015). Multiple studies have leveraged CNVs as a tracking tool to reconstruct clonal
dynamics of breast tumour initiation, invasion and metastasis (Casasent et al., 2018;
Navin et al., 2011; Wang et al., 2014). By combining whole-genome amplification and
sequencing, Navin et al. identified several genetically distinct clones in breast tumours
that arose during sequential clonal expansions despite a low sequencing coverage of
6% (Navin et al., 2011). Subsequent work from Navin et al. has led to the devel-
opment of Topographical Single Cell Sequencing (TCSC), a method that combines
laser capturing and single-cell RNA sequencing to preserve the spatial context while
measuring CNVs. Application of this method to several ductal carcinomas showed
distinct CNV profiles between ductal carcinoma in situ (DCIS) and invasive ductal
carcinoma (IDC). Moreover, they observed that cells harboring the same CNV profile
were not spatially restricted overall, confirming the migratory nature of IDC cells
(Casasent et al., 2018). In a recent study, Campbell et al. developed "clonealign", a
stastical tool to link transcriptomic profiles to genomically defined clones assuming
only an e ect of copy-number dosage on transcript abundance (Campbell et al., 2019).
They demonstrated the power of the technique by identifying clone-specific phenotypes
in a triple-negative breast cancer PDX. However, one requirement of clonealign is the
presence of complex structural genomic rearrangements present in most but not all
cancer types.
Another class of endogenous markers typically used for lineage tracing includes
SNVs and small indels. Both frequently occur in non-coding regions in somatic cells
with no phenotypic consequence. Several studies have successfully used SNVs from
bulk DNA sequencing to infer phylogenetic trees (Abbosh et al., 2017; Gao et al.,
2016; Ju et al., 2017). Like CNVs, SNVs can be identified in single-cell whole genome
sequencing (scWGS) or single-cell whole-exome sequencing (scWES) data. However,
the di culty with detecting SNVs in single cells is due to the sparse distribution of
SNVs in the genome, making it a challenge to detect the same SNVs in a large number
of cells. Nevertheless, this method has been utilized to delineate the clonal evolution
in healthy and tumour tissue (Leung et al., 2017; Lodato et al., 2015; Xu et al., 2012).
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1.4 Single-cell transcriptomics meets lineage trac-
ing
Neither state nor lineage information alone provide the full picture of heterogeneous
cellular states and the ancestral relations between them. While scRNA-seq technologies
enabled the construction of comprehensive transcriptional atlases, there is no direct
capture of long-term dynamic relationships between individual cells or between cells
and their progeny. Parallel advances in sequencing-based lineage tracing methods now
facilitate the mapping of clonal fates onto the transcriptional cell states. These ap-
proaches are incredibly powerful and o er the opportunity to integrate complementary
information about both cell state and cell lineage and the assessment of gene-expression
changes as a function. To achieve barcode profiling from single-cell transcriptomes, most
methods rely on a similar experimental design by embedding a barcode sequence into
the 3’ UTR of a constitutively transcribed fluorescent protein allowing it to be captured
on single-cell RNA platforms using oligo-dT beads for library preparation (Figure 1.5).
The first innovations that included expressed lineage barcodes to be read from
mRNA in whole-transcriptome scRNA-seq were single-cell GESTALT (scGESTALT)
(Alemany et al., 2018), lineage tracing by nuclease-activated editing of ubiquitous
sequences (LINNAEUS) (Spanjaard et al., 2018) and scScarTrace (Raj et al., 2018).
These CRISPR-Cas9 based methods rely on the transcription of Cas9-induced mutations
in a genomic target site that functions as a unique evolvable barcode allowing the
simultaneous quantification of the clonal history, as well as recovering the transcriptome
of single cells. Due to the activity of Cas9 over several hours, barcoding occurs
sequentially resulting in complex scar patterns (Baron and van Oudenaarden, 2019).
This dynamic barcoding process o ers a powerful tool enabling the reconstruction of
multi-branching lineages. The first three experimental approaches relying on CRISPR-
Cas9 to label single cells focused on clonal dynamics in zebrafish embryogenesis
(Alemany et al., 2018; Raj et al., 2018; Spanjaard et al., 2018). Chan et al. further
implemented the CRISPR-Cas9 genetic lineage tracing technology in mice to study
lineage relationships during early embryogenesis (Chan et al., 2019). They generated a
transcribed and evolving molecular recorder consisting of a synthetic Cas9 target site
including three cut sites and a static 8 bp integration barcode. Using a refined version
of their molecular recording system, Quinn and colleagues explored clonal dynamics
in a mouse model of metastasis (Quinn et al., 2021). Their findings identified driver
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genes of metastatic capacity and showed that metastatic transcriptional signatures
were pre-existing and shared between clonally related cells.
The cummulative editing nature of these approaches allow lineages to be reconstructed,
however Cas9 degradation can restrict the time interval of the lineage tracing process.
Most CRISPR-Cas9 barcoding systems rely on introducing random insertions and
deletions through double-strand break repair by non-homologous end joining (NHEJ).
To this point the extent and e ect of potential o -target double-strand e ects remains
unknown. Moreover, lineage information could potentially be lost by the generation
of multiple DNA double-strand breaks in close proximity resulting in the excision of
the intervening sequence. In order to reconstruct the full lineage, all edits must be a
recovered which can be a problem considering that barcode transcripts expressed in cells
could just be undetected in the mRNA profile. While CRISPR-Cas9-based technologies
are the pioneer technique for whole-organism lineage tracing, these approaches su er
from the drawback of requiring the generation of transgenic animals.
Figure 1.5 Integrative technologies for lineage tracing at single-cell level. There are
two major barcode designs: cumulative, "evolving" DNA barcodes (a) or integration DNA
barcodes (b). Both experimental designs rely on embedding the barcode sequence into the 3’
UTR of a constitutively transcribed fluorescent protein allowing the barcode to be expressed
as mRNA and detected with scRNA-sequencing as part of each single-cell transcriptome. The
methods di er in their barcode integration by using either a lentivirus (LARRY, CellTagging),
transposase (TracerSeq, LINNEAUS, Chan et al.) or CRISPR-Cas9 targeting of single guide
RNA arrays (scGESTALT, ScarTracer). scGESTALT, single-cell genome editing of synthetic
target arrays for lineage tracing; LINNEAUS, lineage tracing by nuclease-activated editing
of ubiquitious sequences; LARRY, lineage and RNA recovery. Adapted from Marine et al.
(2020).
One alternative for CRISPR-Cas9 based methods is TracerSeq, a transposon-based
barcoding approach (Wagner et al., 2018). TracerSeq makes use of the Tol2 transposase
system to randomly integrate a pool of barcodes located in the GFP 3’ untranslated
region. While the progressive asynchronous integration of the plasmid into the genome
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over cell divisions allows the reconstruction of phylogenetic trees without inducing
unpaired double-strand breaks or generating identical edits as with Cas9-based methods,
it still relies on injection or electroporation (Wagner et al., 2018).
The implementation of DNA barcoding has utilized an alternative approach for
linking cell origin and states across time based on DNA barcoding. In contrast to
CRIPSR-Cas9 based technologies, virus-based cell labeling is easier to use without
complex genetic manipulation. In a first example, Biddy et al. established a method,
CellTagging, to track fibroblasts to endoderm progenitors in vitro using sequential
rounds of cell labeling (Biddy et al., 2018). To enable the reconstruction of lineage
trees, they used several indexed libraries in subsequent infection rounds to map lineage
relationships. The results of the study suggest the existence of a privileged cell state
shared between clonally related cells, which predefines the reprogramming potential
(Biddy et al., 2018). Further analysis of the gene expression profiles identified a predic-
tor gene, Mettl7a1, that correlated with increased e cacy for successful reprogramming.
A similar approach was applied by Weinreb et al., who also used a lentiviral-barcoding
tool, LARRY (lineage and RNA recovery), to study cell fate decisions in haematopoietic
progenitor cells and to correlate early gene expression profiles to later fate potentials
(Weinreb et al., 2020).
Collectively, these findings highlighted that these technologies have the power to
resolve di erent clonal origins between similar cell states and moreover, enable linking
of lineage behavior to gene expression (Wagner and Klein, 2020).
1.5 Spatial tumour heterogeneity
1.5.1 Molecular profiling of tumours in space
Tissues, including tumours, are composed of a mixture of cell types and states whose
spatial organisation is fundamentally related to its function and interactions. The
molecular makeup of tumours highly depends on external factors, such as the tu-
mour microenvironment and site-specific features. Previous work using multiregion
sequencing strategies has provided evidence of spatial intratumour heterogeneity in
multiple tumours, with spatially separated genotypes followed by evolving pheno-
typic intratumour diversity (Gerlinger et al., 2014, 2012). Others have highlighted
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the importance of the niche on clonal fitness in the tumour, revealing intratumour
heterogeneity in various cancer types across multiple spatial scales (McPherson et al.,
2016; Sottoriva et al., 2015, 2013). However, most of these studies above have been
using bulk genomic profiling obscuring the full picture of the existing heterogeneity.
While massively parallel scRNA-seq approaches allow profiling of the full transcriptome
with single-cell resolution, these techniques rely on tissue dissociation and, thus, do
not contain the spatial context. Conversely, in situ hybridization techniques measure
the spatio-temporal patterns of gene expression, but are limited in their scalability.
Over the last few years, new highly multiplexed epitope imaging methods have been
developed, such as serial immunofluorescence imaging, CyTOF imaging mass cytometry
and multiplexed ion beam imaging (Angelo et al., 2014; Giesen et al., 2014; Lin et al.,
2015). These approaches have greatly contributed to our understanding of structural
tissue organisation, allowing morphological classifications especially between di erent
cancer types (Crosetto et al., 2015). Development of spatial transcriptomics methods
in parallel have given us further insights into molecular processes on subcellular level.
Ultimately, simultaneous measurements of genomic, transcriptomic and proteomic
networks in situ would need to be acquired in order to fully understand the complex
cellular processes and their dependence on both the microenvironment and tissue
morphology.
1.5.2 Spatial transcriptomic approaches
Resolving spatial transcriptomics has been a long-term challenge, starting with fluores-
cence in situ hybridisation (FISH)-based approaches to current spatial multiplexed
whole transcriptome detections at single-cell resolution. Historically, spatial patterns
were visualized through direct or in situ staining of a small subset of genes. In situ
hybridization involved hybridisation of a labelled oligonucleotides to mRNA molecules
within a cell to study gene expression in a spatial context. Recent advances of this ap-
proach resulted in the development of single-molecule fluorescence in situ hybridization
(smFISH). This quantitative method relies on multiple fluorescently labeled oligonu-
cleotide probes that are hybridized along the target mRNA transcript and are imaged
as di raction-limited spots, which are counted to quantify the expression level of the
target gene. Moreover, smFISH has nearly 100% detection sensitivity and can be
applied to whole tissue sections (Itzkovitz et al., 2012; Lyubimova et al., 2013; Raj et al.,
2008). Although this approach allows robust transcript quantification in morphological
intact tissue, the number of transcripts that can be simultaneously detected is limited
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by the number of spectrally resolvable fluorophores. Subsequently, e orts have been
made to increase the numbers of detectable mRNA species at single cell resolution with
multiplexed smFISH approaches, including temporal and spectral mRNA barcoding
(Lubeck and Cai, 2012; Lubeck et al., 2014). While spectral barcoding visualizes the
target with a specific combination of fluorophores, temporal barcoding uses multiple
cycles of smFISH hybridization and stripping to label the same RNA molecule in a
predefined colour sequence with a limited pool of fluorophores. In this manner, the
number of detectable transcripts scales as FN , in which F represents the number of
dyes and N the number of hybridization cycles. This approach was called sequential
fluorescence in situ hybridization (seqFISH) (Lubeck et al., 2014). Over the years, the
detection ability of seqFISH was significantly scaled up from 12 genes in fixed cells up
to 10,000 cells in tissue sections, resulting in the development of seqFISH+ (Eng et al.,
2019; Lubeck et al., 2014).
Since temporal barcoding is prone to errors through false-negative hybridization or
tissue movement resulting in barcode switching, Chen et al. developed a novel error
correcting barcode system, multiplexed error robust FISH (MERFISH) (Chen et al.,
2015). However, MERFISH requires a large number of encoding probes to hybridize to
the target molecule, and is, therefore, limited to longer transcripts only (>3 kb). A
complementary method called spatially-resolved transcript amplicon readout mapping
(STARmap) was introduced by Wang et al., leveraging a combination of hydrogel-based
chemistry, target signal amplification and in situ sequencing. In contrast to similar in
situ sequencing methods, STARmap uses a novel error-reduction by dynamic annealing
and ligation (SEDAL) sequencing approach in which sequencing errors in any cycle
cause misdecoding and are e ectively rejected.
An alternative to FISH is to sequence the RNA directly in the cells or tissue.
Here, a predefined set of transcripts is targeted by specific padlock probes to create
rolling-circle amplification product which can be identified in two ways: The fluorescent
in situ sequencing (FISSEQ) method sequences the amplified cellular RNA content
directly, whereas Ke et al. introduced a 4 nt barcode into the padlock probe and
sequenced this barcode in situ instead (Ke et al., 2013; Lee et al., 2014).
Other technologies have introduced immobilized reverse-transcription oligo(dT)
primers with positional molecular barcodes either on glass slides (Stahl et al., 2016) or
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coupled to microparticles ("beads") arrayed onto rubber-coated glass coverslips (Ro-
driques et al., 2019). Similar to single-cell RNA sequencing, each barcode allows spatial,
cellular and molecular assignment of the mRNA molecule which is then sequenced via
SOLiD (sequencing by oligonucleotide ligation and detection) chemistry. In contrast to
the targeted imaging-based approaches, these methods o er unbiased capture of the
transcriptomic landscape with a relatively high throughput, however they still lack
subcellular resolution.
The ultimate goal is to perform multimodal spatial profiling that allows parallel
measurements of genome, transcriptome and proteome. One of the first integrative
technologies was recently presented by Argelaguet et al. who generated a single-
cell multi-omics map using single-cell nucleosome, methylome and transcriptome
sequencing during gastrulation in mouse embryos (Argelaguet et al., 2019). In another
study, seqFISH+ was combined with DNAseq+ for genomic analysis and sequential
immunofluorescence measurements for protein expression (Takei et al., 2021).
Chapter 2
WILDseq: Development of an
integrative barcoding approach
The work described in this chapter was the result of a collaboration with an inter-
disciplinary team within the IMAXT lab. The design and all experimental work was
performed by me. The analysis pipelines for the barcode assignment were built by
Dr. Kirsty Sawicka. The single-cell RNA sequencing analysis was performed under
the guidance of Dr. Kirsty Sawicka. Fluorescent cell sorting was performed by the
Flow Cytometry Core Facility and sequencing was performed by the Genomics Core,
including single-cell RNA library preparation.
2.1 Introduction
Tumours are composed of a heterogeneous mixture of individual cells that di er from
each other in their genetic, epigenetic and transcriptional landscape. This intrinsic het-
erogeneity, revealed through recent advances in high-throughput sequencing, provides
a fuel for cancer evolution leading to di erent cell fates, such as death versus survival
of cancer cells upon therapeutic intervention. Thus, tumour heterogeneity represents a
major clinical obstacle that results in short-lived success of most drug treatments.
Cancer progression follows evolutionary principles which result in clear phylogenetic
signatures along the way. Lineage tracing approaches have the power to map these
signatures and infer tumour cell ancestry from the pattern of shared features across
tumour subpopulations. Prospective lineage tracing relies on labelling individual cells
at an early time point in order to measure population dynamics at clonal resolution.
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One limitation of lineage tracing approaches is that the main focus relies on genotypic
relations of cells to each other, but lacks any information about the phenotypic state
of the cell. Single-cell RNA sequencing (scRNA-seq) technologies provide the potential
to explore the transcriptional states of thousands of individual cells, thereby capturing
diversity in heterogeneous cell populations. Thus, combining lineage tracing and
scRNA-seq would enable single-cell omic-scale profiling, while simultaneously reporting
lineage information.
Here we present a single-cell resolution clonal tracking approach, which we have
named "WILDseq" (Wholistic Interrogation of Lineage Dynamics by sequencing), based
on a lentiviral barcoding system, permitting the parallel capture of individual cell state
and cell lineage. In this context, clones refer to a population of cells which inherited
the same WILDseq barcode from the founder clone. Clonal labelling starts at the
point of infection. "WILDseq" integrates complementary information about cell lineage
and cell state into a unified view of clonal dynamics over time. We uniquely labelled
individual cells of the heterogeneous 4T1 breast cancer cell line with our heritable,
expressed WILDseq barcode and analysed clonal distributions in vitro and in vivo.
In a first proof-of-principle experiment, we demonstrated the ability to capture gene
expression and lineage information in parallel in vitro using WILDseq. Our results
not only exemplified the functionality of the WILDseq platform in capturing clonal
identity and gene expression simultaneously, but also highlighted the importance of
adding a "bottlenecking" step in the pipeline. Thus, we established and optimized a
bottlenecking strategy allowing us to observe clonal dynamics in a heterogeneous model
of breast cancer in vivo. These experiments set the basis to explore clonal changes in
cancer progression under therapeutic pressure in our following experiments.
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2.2 Material and Methods
2.2.1 Cell culture
The mouse mammary tumour cell lines 4T1 (ATCC) and D2A1-m2 (Jungwirth
et al., 2018) were cultured at 37 °C in DMEM (Gibco), supplemented with 10%
heat-inactivated fetal bovine serum (Gibco) and 50 U/mL of penicillin-streptomycin
(Gibco) under 5% CO2 culture conditions. The 293FT (Thermo Fisher Scientific) pack-
aging cell line for virus production was cultured following manufacturer’s instructions.
Cells were split into fresh culture medium every two to three days by trypsinization
with TrypLE reagent (Gibco) quenched with complete DMEM, and maintained at cell
density of 70-90%.
2.2.2 WILDseq library design and cloning
To generate the WILDseq library, a barcode cassette was introduced into the 3’UTR
of zsGreen in the pHSW8 lentiviral construct, using PCR (Q5 High-Fidelity DNA
Polymerase, NEB) and Gibson Assembly (NEB). The pHSW8 backbone was constructed
in a four-way Gibson Assembly (NEB) by inserting an antiparallel cassette of a PGK
promoter for the expression of zsGreen, a cloning site for high-diversity barcode
libraries and a synthetic polyA signal into an empty pCCL-c-MNDU3-X backbone
(Cat.No.81071, Addgene). The barcode library was designed by generating 12 nt
variable sequences using the R package DNABarcodes (Buschmann, 2017) and a set
Hamming distance of 5. The resulting oligo pool was purchased as a custom oligo pool
(Twist Bioscience). The barcode library was built by annealing reverse complement
oligos (BarcodeOligo_Fwd/Rev) and amplifying the product by PCR for 20 cycles
(using Assembly_Fwd/Rev primers). Each oligo contains a specific PCR handle, a
12-bp variable region and 20-bp constant linker (2.1).
The amplified barcode library (5’-AGCGATTCAAAGTTCTATCCGNNNNNNNNNN
NNtgcatcggttaaccgatgcaNNNNNNNNNNNNATCGTATAGTAAACGAGCGCAT-3’)
was purified by columns (Gel extraction kit, Quiagen) and the vector backbone was
prepared by digestion with SwaI (NEB).
(Ns denote WILDseq barcode sequences, lowercase denotes linker sequence, uppercase
denotes PCR handles in the barcode cassette)
10 ng amplified WILDseq barcode library was cloned into 100 ng digested pHSW8
vector in a 50 µL Gibson reaction (NEB), cleaned with a PCR purification kit (Qiagen)
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and eluted in 15 µL H2O. The entire reaction volume was transformed into 10-—
electrocompetent E.coli cells (NEB) and cells were expanded in liquid culture for 18 h
at 37 °C. Plasmid DNA was extracted with a MaxiPrep Plasmid Plus kit (Qiagen).
2.2.3 Virus production and transduction
Lentiviral particles were produced by cotransfecting 293FT cells (Thermo Fisher
Scientific) with transfer plasmid and the standard packaging vectors pMDL, CMV-Rev
and VSV-G using either Lipofectamine 2000 (Invitrogen) or the calcium-phosphate
transfection method (Wigler et al., 1978). After 16-18 h, media was changed and cells
were supplied with fresh growth media. Viral supernatant was collected 48 h after
transfection and applied to cells immediately following filtering through a 45 µm syringe.
Alternatively, viral supernatant was placed at 4 °C for short-term storage or -80 °C for
long-term storage. When necessary, virus was concentrated using ultracentrifugation.
Lentiviral titer was determined by serial dilution and measurement of fluorescence
via flow cytometry. Cells were infected with lentiviral barcode libraries at a very low
multiplicity of infection (≥ 0.2), allowing only one barcode per cell. After two days in
culture, cells expressing zsGreen (zsGreen+) were sorted using FACSAria cell sorter
(BD Bioscience).
2.2.4 Library complexity analysis
To obtain a comprehensive estimate of the library complexity, barcodes were amplified in
four separate PCR reactions with primers containing Illumina adaptors from barcoded
plasmid library. All reactions were pooled together, concentrated and purified on
a column and then sequenced on one lane of an Illumina HiSeq4000. Reads that
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contained the WILDseq barcode motif were identified and extracted from the FASTQ
files. Reads reported for each WILDseq barcode were filtered based on a 90% percentile
cut-o . The resulting whitelist was further filtered for barcodes containing the common
linker region.
2.2.5 Bottlenecking and characterization of WILDseq pools.
4T1 or D2A1-m2 cells were infected with WILDseq library at low MOI (≥ 0.2-0.3).
Two days after infection, various numbers of zsGreen+ cells were sorted into pools.
Individual cell pools were cultured for two weeks allowing the barcode clones to stabilise
in culture. A whitelist was generated for each pool via reverse transcription.
2.2.6 Whitelist generation of WILDseq barcodes
In order to generate a representative whitelist of expressed barcodes in our pools,
RNA was extracted from WILDseq transduced cells (High Pure RNA isolation kit,
Roche) and reverse transcription (RT) was performed using the Superscript IV reverse
transcription kit (Invitrogen) and a target site-specific primer with a unique molecular
identifier (UMI) and an Illumina sample index. cDNA was amplified by PCR (Q5
High-Fidelity DNA Polymerase, NEB) using primers containing Illumina-compatible
adapters and sample indices (RTWhitelist_Fwd/Rev). Alternatively, 1 µg gDNA was
extracted from WILDseq transduced cells (Blood&Cell Culture DNA Kit, Qiagen) and
the barcode amplified by PCR using primers containing Illumina-compatible adapters
(gDNAWhitelist_Fwd/Rev). PCR products were purified via gel extraction (Qiagen)
and quantified by Qubit. The library was sequenced on an Illumina MiSeq with a
custom sequencing primer for Read1 (CustomRead1).
Reads that contained the WILDseq barcode motif were identified and the number of
unique UMIs supporting each barcode was calculated. If barcode sequences amplified
from gDNA were also available an additional filtering step was introduced excluding any
barcode that was not detected in both RT-PCR and gDNA library. Based on the UMI
counts, the top 90th percentile of detected barcodes was taken and collapsed for PCR
and sequencing error correction using hierarchical clustering and combining sequences
with a Hamming distance less than 5. Based on the UMI count, true barcodes were
identified and included in the whitelist.
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2.2.7 Single cell library preparation
Cells were dissociated using TrypLE Express (Gibco) and counted using a hemocy-
tometer. Cell concentration was adjusted to 500 cells/µL in phosphate-bu ered saline
(PBS) + 0.04% bovine serum albumin (BSA, Sigma Aldrich), then processed on the
10X Genomics platform using the Chromium Gene Expression 3’ v3.1 dual index kit,
according to the manufacturer’s instructions. Tumour tissue was harvested from mice
injected with a pool of barcoded 4T1 cells. Tissue was minced prior to enzymatic and
mechanical dissociation using the gentleMACST M Octo Dissociator (Miltenyi Biotec)
and the respective kit (Tumour Dissociation Kit mouse). Tissue was processed into
single cell suspension following manufacturer’s instructions and filtered through 70 µm
filter (Miltenyi) to remove any remaining larger particles from the single-cell suspen-
sion after dissociation. For in vivo samples, a live-dead sort with propidium iodide
(Biolegend) was included to remove dead cells and debris prior to counting. Three
million cells were sorted, pelleted and resuspended in 1 mL PBS + 0.04% BSA (Sigma
Aldrich) prior to counting with a hemocytometer. The final single cell suspension was di-
luted as required and sequenced using the Gene Expression 3’ v2.1 or v3.1 dual index kit.
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2.2.8 Enrichment library preparation
WILDseq barcodes were further amplified from cDNA libraries with WILDseq-specific
primers containing Illumina-compatible adapters and sample indices (Enrich_Fwd/Rev
primers).








Female, six to eight week-old Balb/C mice were purchased from The Charles River
Laboratory. All orthotopic injections were performed using 60,000 mouse mammary
tumour cells resuspended in 50 µL of a 1:1 mix of PBS and growth-factor reduced
Matrigel (Corning). Injections were done into the fourth mammary gland. Primary
tumour volume was measured using the formula V=1/2(L ◊ W 2), in which W is width
and L is length of the primary tumour. Tumours were collected 21 days post tumour
cell injection.
2.2.10 Bioinformatic analysis of WILDseq scRNA-seq data
Read alignment and generation of expression matrix.
The Cell Ranger v3.0.1 pipeline (https://support.10xgenomics.com/ single-cell-gene-
expression/software/downloads/latest) was used to process data generated by the
10X Chromium platform. The pipeline relies on STAR for alignment and was used
in conjunction with a custom reference genome, created by adding the sequence
of the zsGreen-WILDseq barcode transgene as a new chromosome to the mm10
mouse genome. To create a new reference genome compatible with Cell Ranger,
we followed the instructions from 10X Genomics on building a custom reference
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(https://support.10xgenomics.com/single-cell-gene-expression/software/pipelines /lat-
est/using/tutorial_mr#runmkref). In brief, we first modified the reference genome
used during alignment by adding the full lentiviral plasmid sequence including the
transgene above. We then created a custom gene transfer format (GTF) file, containing
our custom transgene annotation, followed by indexing of the FASTA and GTF files,
using the Cell Ranger mkref function.
Single cell sequencing analysis using Seurat
The digital gene expression matrices generated were then analysed with the Seurat R
package using a standard pipeline (Stuart et al., 2019). Seurat was used to perform
initial filtering of digital gene expression (DGE) data files as a quality control step.
We first removed cells that had over 10,000 or less than 200 unique detected genes.
This process was also used to filter out cells in which the proportion of the UMI count
attributable to mitochondrial genes was greater than 12%. Reads mapped to the
zsGreen-WILDseq barcode transgene were removed from the count matrix allowing
unbiased clustering downstream.
Following DGE filtering, data was normalised by employing a global-scaling normaliza-
tion method “LogNormalize” and cell cycle scores were calculated. For each cell, cell
cycle scores were generated based on canonical markers for each cell cycle phase using
the Cell-Cycle vignette (https://satijalab.org/seurat/v3.1/cell_cycle_vignette.html).
The data was processed with SCTransform, a statistical approach for modeling, normal-
isation and variance stabilisation. During this process, calculated cell cycle scores were
regressed out. The normalised values were then used as input for principal component
analysis (PCA). Subsequently, PCs were used to calculate cluster of cells with the
Louvain algorithm. Resulting clusters were visualised using UMAP and di erential
expression analysis was performed using the non-parameteric Wilcoxon rank sum test.
Barcode demultiplexing
WILDseq barcode demultiplexing from transcriptomics data. Reads map-
ping to the zsGreen-WILDseq barcode transgene were extracted from the processed
and filtered BAM file produced by Cell Ranger. The resulting BAM file was converted
into a fastq file using the tool bamtofastq from 10X Genomics
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(https://support.10xgenomics.com/docs/bamtofastq). Reads containing the full bar-
code sequence (20 nt constant linker with a 12 nt region on either side) were identified
and processed for further downstream analysis. The resulting barcode list was mapped
to the whitelist, generated for each WILDseq cell pool, using Bowtie (Langmead
et al., 2009). Next, cell barcodes and UMIs of all reads were extracted from BAM file
generated above and then merged with WILDseq barcodes based on barcode ID/name
using a custom R script. WILDseq barcodes were grouped by cell barcodes, followed
by counting the number of unique UMIs for each cell barcode-WILDseq barcode. The
matrix was filtered for WILDseq barcodes represented by at least two independent
reads and more than 50% of barcode mapped reads from the cell supported assignment.
WILDseq barcode demultiplexing from enrichment PCR data. Using the
package UMI tools (Smith et al., 2017), a whitelist of cell barcodes was generated from
the corresponding transcriptomic run to extract 10X cell barcodes and UMIs from the
raw read files. The sequence corresponding to the full barcode sequence (20nt constant
linker with a 12 nt variable region on either side) was extracted from each read and
then mapped to the WILDseq barcode whitelist using Bowtie. A WILDseq barcode was
assigned to a cell if there were at least 10 UMIs which matched the barcode to the cell
and at least twice as many UMIs supporting this assignment compared to the next best.
Clone calling in 10X and enrichment PCR dataset. Barcode assignment
from these two pipelines was compared and WILDseq barcodes identified by both
methods were included in the final matrix. On the rare occasion, that the assignment
did not match no clonal barcode was assigned. In the case that a WILDseq barcode
was only detected by one method, a further more stringent filtering step was included.
WILDseq barcodes only appearing in the 10X scRNA-seq data were required to have
at least 5 UMIs, while WILDseq barcodes only observed in the enrichment PCR data
needed to have at least 30 UMIs. The final barcode matrix was added to the metadata
of the corresponding Seurat object.
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2.3 Results
2.3.1 Design of the WILDseq platform and proof-of principle
experiment
Droplet-based approaches for single-cell transcriptomics rely on two indexing strategies
that allow deconvolution of pooled RNA-seq data into single cell gene expression
profiles: a cell barcode (CBC) and a unique molecular identifier (UMI). In order to
combine gene expression analysis with clonal lineage tracing, we built the WILDseq
platform to add this additional layer of information (Figure 2.1a).
WILDseq is a lentiviral-based approach relying on uniquely labelling individual
cells with a heritable barcode which can be captured as an expressed transcript by
scRNA-seq. To deliver and capture WILDseq barcodes, we designed the "WILDseq
vector", a third-generation lentiviral vector that contains a phosphoglycerate kinase
(PGK)-driven expression cassette terminated with a strong synthetic polyA signal
(Figure 2.1b). To prevent the internal polyA signal from interfering with the lentiviral
particle production, the entire expression region was cloned in reverse orientation with
respect to the genomic promoter. The expression cassette, moreover, contains a zsGreen
reporter fluorophore allowing the cell sorting of infected cells. We chose zsGreen due
to its brightness in flow cytometry and to specifically avoid fluorophores with known
immunogenicity (Stripecke et al., 1999). The positioning of the barcode cassette
relative to the polyA signal by ≥120-130 base pairs (bp) was optimised for faithful
transmission of WILDseq barcodes into scRNA-seq libraries using standard oligo-dT
capture chemistry. Each barcode sequence was designed with a hamming distance of 5,
where the hamming distance refers to the number of di erent positions between two
strings of equal length, and thus allowing to correct up to 2 errors per barcode sequence.
To increase the complexity of the library, we combined two barcode sequences through
a common linker sequence and amplified the whole barcode cassette via PCR before
inserting it into the WILDseq vector via Gibson Assembly. The final library consists
of ≥1,600,000 potential barcode combinations. To ensure robust WILDseq barcode
capture, we developed a one-step PCR enrichment strategy to specifically enrich
WILDseq barcode transcripts out of the indexed, amplified cDNA of the transcriptome
(discussed in detail later 2.3.3).
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Figure 2.1 WILDseq pipeline and barcode design. a| Schematic illustration of WILDseq
platform. Cells are infected with WILDseq library at a low MOI allowing only one barcode
per cell. Infected cells are sorted two days post infection. WILDseq labelled cells express
unique barcodes enabling clonal tracking with single-cell RNA sequencing using the 10X
Genomics platform. An additional PCR step for the WILDseq barcode is included that
specifically enriches for barcode sequences from the pooled cDNA and thereby, increases
the assignment of WILDseq barcodes. 10x BC corresponds to cell barcode (index unique to
each bead). UMI, unique molecular identifier (index unique to each bead oligo). WILDseq
barcode specific for each clone (WILDseq transcript highlighted as red mRNA.) b| Schematic
illustration of WILDseq library. Lentiviral construct containing two 12 nt WILDseq barcode
sequences in the 3’ UTR of zsGreen, followed by a synthetic polyadenylation signal. The
spacer sequences places the barcode in the optimal distance to the polyA signal for faithful
transmission into scRNA-seq library using standard oligo-dT capture. The barcode sequences
were designed with a hamming distance of 5 to account for PCR and sequencing errors.
Library complexity equals ≥1.6 million barcodes in total.
In a pilot experiment, we performed scRNA-seq on a pool of individually labelled
4T1 breast cancer cells, analyzing ≥10,000 cells in total using the WILDseq platform
(Figure 2.2a and b).
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Figure 2.2 WILDseq barcode detection in 4T1 cells in vitro. a| UMAP representation
of scRNA-seq in vitro 4T1 dataset resolved in 12 individual clusters (highlighted in di erent
colours). b| UMAP representation of scRNA-seq in vitro 4T1 dataset highlighting the
expression of the WILDseq barcode transcript in blue. c| Violin plot of WILDseq barcode,
Vim and Krt18 expression in scRNA-seq in vitro dataset. WILDseq barcode was di erentially
expressed in population comparable to Vim.
Briefly, we infected 4T1 cells at a low multiplicity of infection (MOI) with the
WILDseq barcode library such that each cell was labelled with a single, unique barcode.
The library complexity is su cient to label 10,000 cells in an experiment with less than
1% barcode overlap between clones. Two days post infection, transduced cells were
sorted and recovered in culture. Overall, we assigned ≥40% of the cells a barcode. Gene
expression levels of the barcode were highly variable within the population comparable
to Vim (Figure 2.2c). For the vast majority of barcode expressing cells (≥90%),
we detected only one WILDseq barcode per cell as expected. In less than 3% of the
population we observed 2-3 cells with the same barcode and only one barcode was
represented by six cells.
To study clonal dynamics in vivo, we therefore needed to bottleneck our population size
- too large a starting population and the number of founding clones will be too large to
record su cient data of an individual clone using single-cell RNA sequencing, too small
a starting population and it will lack the diversity to capture phenotypic heterogeneity.
Based on the assumption that we capture ≥8000 single-cell transcriptomes in one
scRNA-seq run, we decided to bottleneck the population to 250 cells with the hope of
observing around 50-100 unique clones.
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2.3.2 Robust detection of WILDseq barcodes in vivo
To demonstrate the capacity of our WILDseq technology to track clones in vivo, we
established a WILDseq labelled population originated from 250 cells and injected
50,000 cells of this pool into the mammary fat pad of a Balb/C mouse. Specifically,
we labelled 4T1 cells with our WILDseq barcode library, sorted 250 zsGreen positive
cells two days post infection and stabilised the barcoded cell population in culture.
Importantly, WILDseq labelled 4T1 cells were prepared such that each cell carries a
distinct WILDseq barcode. 21 days after fat pad transplantation, we collected and
dissociated the tumour into single cells which were processed through our WILDseq
pipeline.
Figure 2.3 WILDseq barcode detection in vivo. a| UMAP representation of 250 cells
pool in vivo with barcode expression highlighted in red. b| UMAP representation of extracted
tumour cell clusters with di erent WILDseq clones highlighted. Five clones were robustly
detected with clone 236 dominating the tumour.
We robustly detected a WILDseq barcode in over 58% of all tumour cells. However,
over 50% of the tumour was dominated by clone 236 out of the five di erent clones
we assigned (clone 24, 30, 151, 223 and 236) (Figure 2.3). The other four barcodes
only accounted for 10 assigned reads. Due to the lack of clonal diversity in the pool
in vivo, we attempted to improve our bottlenecking strategy, which is a critical step
to the success of the method. In parallel, we also developed a new strategy to create
a reference list of barcodes, from now on referred to as a "barcode whitelist", to be
able to robustly assign WILDseq barcodes to cells and to quantify the relative amount
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of clones present in each of these pools (Figure 2.4a). Notably, we also observed a
small fraction of barcodes (< 5% per cluster) being assigned outside of the tumour
clusters. We believe that this is due to technical noise, resulting in mis-assignment of
reads to the wrong cell barcode. This is supported by the fact that increase of the
level of stringency of the barcode assignment reduced the mis-assignment outside of
the tumour clusters. In order to increase our clonal diversity, we tested di erent clonal
pool sizes as well as di erent bottlenecking and pooling strategies. We generated two
larger populations, consisting of 1000 (population 1) and 1250 cells (population 2),
using a single sorting step. Additionally, we sorted multiple 10 cell populations and
pooled them into three 120 cell pools, which we kept separate until immediately before
mouse injections (pool 1). A similar approach was used to create a pool with 750 cells
consisting of three independent 250 cell populations that are just combined before
injection in order to increase clonal competition in vivo (pool 2).
Briefly, we extracted RNA from the pools which was then used for reverse tran-
scription (RT) reaction with a custom primer detecting our WILDseq transcript. We
furthermore included a unique molecular identifier (UMI) in our primer allowing the
identification of PCR duplicates generated during library preparation. Barcode se-
quences were amplified and adapter and index sequences introduced by PCR. The
library was then analysed via NGS. The resulting sequencing information was used
to build a whitelist and a bowtie index to which barcode sequences from single cell
RNA sequencing data could be compared, thereby allowing the robust calling of clone
identities. To be able to select for the appropriately sized pool, we selected four pools
based on the RT-PCR data of the in vitro pools and analysed them in vivo using
scRNA-seq.
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Figure 2.4 WILDseq barcode detection in vivo and bottlenecking strategy of clone
pools. a| Schematic representation of bottlenecking strategy and generation of barcode
whitelists using an RT-PCR approach. Barcode specific RT-primer included a UMI to account
for PCR errors allowing robust calling of barcodes. Recovery of barcode sequences, followed
by filtering and error-correction resulted in the final whitelist which was used to create a
bowtie index. b| UMAP representations of di erently sized clonal populations and pools with
barcode expression highlighted in red. Populations (Population 1 = 1000 cell population,
population 2 = 1250 cell population) and pools (pool 1 = 3x 120 cell populations, pool 2 =
3x 250 cell populations) were generated based on the bottlenecking pipeline illustrated in (b).
Clonal distributions are illustrated in pie charts including total number of clones. Pool 2
exhibited the highest clonal diversity and number of di erent clones (26 clones).
Analysis of the di erent pools revealed that pooling three 250 cell populations
(pool 2) immediately before injection, exhibited not only the highest diversity in gene
expression but also in clones compared to the other pools in vivo (Figure 2.4b).
This cell pool will be referred to as "WILDseq pool" and was used for all subsequent
experiments. We expanded the three 250 cell populations separately for 14 days and
cryopreserved them as the three parental barcoded 4T1 populations. Although we
sorted more cells in the population based approach neither the expression nor the
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clonal diversity were su cient for our needs. While pool 1 had the second highest
number of clones, we detected fewer barcoded cells overall in our tumour population.
2.3.3 Characterisation of WILDseq pool in vitro
To further characterise our WILDseq pool, we performed scRNA-seq on the barcoded
cells in vitro (Figure 2.5a). The three 250 cell populations were stabilised in culture,
sorted for their zsGreen expression and pooled to form the WILDseq pool immediately
before single-cell library preparation. To increase the barcode detection and therefore
the number of tumour cells for which a clonal lineage could be assigned, we prepared
a barcode enrichment library using amplified, pooled cDNA from the transcriptomic
library as input. Combining the barcodes detected in the transcriptomic library with
those detected in the barcode enrichment library, we were able to robustly assign a
WILDseq barcode to over 50% of the cells (3950 cells out of 7000 profiled cells). In
total, 132 di erent barcodes were observed (Figure 2.5b).
Figure 2.5 Characterisation of 4T1 WILDseq pool in vitro. a| UMAP representation
of WILDseq pool in vitro. Cells with an assigned WILDseq barcode are highlighted in
dark grey or coloured spots. The main driver of clustering was clonality. b| Relative clonal
abundance in the WILDseq pool in vitro. Individual clones are highlighted in di erent colours.
Clones that are present at levels below 1% are illustrated together. In total, 132 WILDseq
barcodes were detected.
We found that cells with the same barcode often clustered together. Clone 132 and
264 in particular exhibited a distinctive gene expression profile and clustered separately.
This suggests that the main source of transcriptomic diversity in vitro is clonality.
Interestingly, those clones that dominated the in vitro population were not the same as
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those most frequently observed in the in vivo tumour generated from this clonal pool,
indicating that although they had a growth advantage under cell culture conditions
they lacked the ability to contribute to the tumour in vivo, possibly due to a lack of
ability to engraft or to survive the conditions present in in vivo.
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2.4 Discussion
Here, we introduce WILDseq, a scRNA-seq compatible clonal lineage-tracing approach
that maps phenotypic cell states to clonal identities. A key advantage of WILDseq
is it’s simple to use and applicable to any cell culture and model system that is sus-
ceptibleu to viral transduction. We built WILDseq by inserting a reverse expression
cassette containing two distinct error-correctable barcode sequences into a lentiviral
vector backbone. Our initial experiment in which we uniquely labelled over 4000 4T1
cells with WILDseq highlighted the importance of adjusting the population size by
bottlenecking. We optimized our bottlenecking strategy to obtain a heterogenous model
system capable of generating su cient data on individual clones while maximising the
clonal diversity. Our final WILDseq pool consisted of three 250 4T1 cell populations
that were used as parental populations for all following experiments. Transcriptomic
characterisation of our cultured WILDseq pool demonstrated that clonality was the
main driver of the di erences in the expression profiles between clones. However,
clustering of WILDseq tumours does not only depend on clonality, but also on external
factors, such as the tumour microenvironment and other influences (e.g. oxygen supply,
vascularisation,...) that modulate the transcriptome within a tumour cells to an equal
or even greater impact than clonality. Finally, the transcriptomic natures we observed
was specific to each of the clones.
Importantly, our WILDseq method o ers the great advantage of integrating data
across experimental treatment conditions. Current analysis methods largely rely on
clear distinguishable transcriptomic markers of cell types for integration which has
been proven di cult when it comes to the identification of the same subpopulation
of cells, as transcriptomics signatures are often masked by transcriptomic changes
induced by external factors (e.g. tumour microenvironment or drug treatment). Future
optimisations of WILDseq may include alternative fluorophores or promoters and
insulator sequences to overcome the limitation of silencing of lentiviral constructs in
certain cell types. Moreover, this approach cannot directly provide information on
spatial context and thus, another improvement could be the integration of in situ
sequencing techniques to receive the full picture.
Currently, there are two technologies available that leverage a similar technology
to WILDseq: LARRY (Weinreb et al., 2020) and Celltag (Biddy et al., 2018). While
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both systems also rely on a lentiviral vector system to deliver a heritable, expressed
barcode, neither of the two systems uses an error-correctable barcode which could
potentially result in problems with barcode assignment due to PCR errors during
library preparation and/or sequencing errors. Furthermore, both systems have only
been applied to culture or hematological studies so far which is of comparative ease
regarding sampling. Recently, Quinn et al. reported the use of a Cas9-based, single-cell
lineage tracer for the first time in a model of lung cancer (Quinn et al., 2021). Their
strategy di ers from our WILDseq approach, however, in that it requires the delivery
of multiple components for the CRISPR system and complicated lineage tree inference
analysis due to the evolvable nature of the barcode. Moreover, we have shown that
the expression of our WILDseq barcode is maintained over long periods of time in
vivo, unlike CRISPR-Cas9 approaches that su er from frequent single-cell barcode
dropouts. Together, we established a novel approach that allows robust integration
of clonal identities and transcriptomic characteristics to elucidate processes of clonal




using WILDseq in breast cancer
The work described in this chapter was the result of a collaboration with an interdis-
ciplinary team. All experimental work was the result of my own work with support
for the animal work from Dr. Ian Gordon Cannell. The analysis pipelines for the
di erential gene expression and pathway analysis was performed by Dr. Kirsty Sawicka.
The patient data analysis was performed by Dr. Ian Gordon Cannell. Fluorescent
cell sorting was performed by the Flow Cytometry Core Facility and sequencing was
performed by the Genomics Core, including single-cell RNA library preparation.
3.1 Introduction
Clonal evolution is a key feature of cancer progression enabling tumour cell populations
to adapt to selective pressures imposed by the tumour microenvironment or therapeutic
interventions and is thought to be the underlying cause of drug resistance. Challenging
a population of tumour cells with a drug could have several di erent outcomes on
the clonal composition and diversity. Drug treatment could result in a population
bottleneck of the tumour cell population followed by reconstitution of the tumour by
a single or multiple resistant clones. Alternatively, the therapy could result in full
remission of the tumour or have no e ect on the diversity of the population. Currently,
most studies have been focused on either the genetic or transcriptional mechanisms
underlying therapy responses, independently lacking the ability to link functional
phenotypes with individual clones. To overcome this knowledge gap, we applied our
WILDseq approach to study the nature of clonal response to therapeutic pressure in
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the syngeneic mammary carcinoma model 4T1. The standard of care treatment for
many breast cancer patients is neoadjuvant or adjuvant chemotherapy consisting of a
combination of taxanes and anthracyclines. Extensive research has been focused on
identifying chemotherapy resistance mechanisms o ering an ideal platform to validate
our WILDseq approach. In this study, we defined resistance and sensitivity signatures of
clones to the frontline chemotherapy docetaxel and the epigenetic anti-cancer drug JQ1.
Moreover, we identified recurrent baseline signatures of our WILDseq clones in vivo.
Analysis of human patient data revealed a strong association between non-responders
and our docetaxel resistance genes, highlighting the clinical relevance of our findings.
We further validated our WILDseq platform in a second triple-negative breast cancer
cell line D2A1-m2 in vivo demonstrating that WILDseq can be applied to any cell
culture system that is amendable to viral transduction. By applying WILDseq to study
the e ect of JQ1 treatment, we uncovered a potential synergy between baseline DNA
damage signaling and JQ1 treatment in suppressing MYC -related signatures as well as
a T-cell dependent resistance mechanism emphasizing the importance of a syngeneic
model. Collectively, our work establishes a unique platform allowing the study of clonal
response to therapy by uniquely distinguishable clones in a heterogeneous population
in vivo and link them to their functional phenotypes.
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3.2 Material and Methods
3.2.1 Tissue preparation for scRNA-seq experiments
Tumour tissue was harvested from mice injected with a pool of barcoded 4T1 cells. Tis-
sue was minced prior to enzymatic and mechanical dissociation using the gentleMACST M
Octo Dissociator (Miltenyi Biotec) and the respective kit (Tumour Dissociation Kit
mouse). Tissue was processed into single cell suspension following manufacturer’s
instructions and filtered through 70 µm filter (Miltenyi) to remove any remaining
larger particles from the single-cell suspension after dissociation. For in vivo samples,
a live-dead sort with propidium iodide (Biolegend) was included to remove dead cells
and debris, collecting three million live cells which were pelleted and resuspended in 1
mL phosphate-bu ered saline (PBS) + 0.04% bovine serum albumin (Sigma Aldrich).
Alternatively, cell concentrations of in vitro WILDseq pool was determined using a
hemocytometer. Finally, cell suspension was submitted for scRNA-seq on the 10X
Genomics platform using the Gene Expression 3’ v2.1 or v3.1 dual index kit.
3.2.2 Animals and in vivo dosing
Female six to eight week-old Balb/C were purchased from The Charles River Laboratory.
60.000 tumour cells were resuspended in 50 µL of a 1:1 mixture of PBS and growth-
factor reduced Matrigel (Corning). All orthotopic injections were performed into the
fourth mammary gland. Primary tumour volume was measured using the formula
V=0.5(L◊W2), in which W is the width and L is length of the primary tumour.
Tumour-bearing mice were treated with either vehicle or with di erent drugs seven
days post transplantation. Mice received intraperitoneal injections of 75 mg/kg JQ1
(dissolved in DMSO and diluted 1:10 in 10% —-cyclodextrin (Sigma Aldrich)) for five
consecutive days followed by two days drug holiday until tumours reached endpoint
or 12.5 mg/kg docetaxel (dissolved in 1:1 mixture of ethanol and Kolliphor (Sigma)
and diluted 1:4 in saline) administered three times a week for two weeks. Three
animals per dose group were used. Vehicle-treated mice were sacrificed 21 days post
tumour transplantation and treated animals were sacrificed when tumour volume
reached that of vehicle treated animals at 21 days. D2A1-m2 tumours were generated
the same way and treated with the following vehicle: 12.5% DMSO in 0.5% sodium
carboxymethylcellulose.
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3.2.3 Di erential gene expression analysis
Di erential gene expression between clones or conditions was assessed using Seurat’s
FindMarkers function with Wilcoxon rank sum test to generate P values and identify
di erentially expressed genes. P-values were generated on a per-sample basis and
combined using the Fisher’s Method. Combined p-values were adjusted for multiple
comparisons using the Benjamini Hochberg correction method and filtered (p<0.05
and logFC<0 for downregulated genes or logFC>0 for upregulated genes). Pathway
analysis was performed using the AUCell R package which enables analysis of the
relative expression of a gene set (e.g. gene signature or pathway) across all the cells
in the scRNA-seq dataset to calculate the enrichment of the input geneset within
the expressed genes for each cell using the "Area Under the Curve" (AUC). Input
genesets were taken from Molecular Signatures Database (MSigDB) C2 curated gene
set collection v7.2 (Mootha et al., 2003; Subramanian et al., 2005) and filtered for
signatures that contained more than 20 genes with detectable expression in our dataset.
Each tumour cell got an AUCell Score for every signature in the MSig DB C2 collection
assigned. AUCell scores were compared across clones or conditions using a Wilcoxon
rank sum test and p-values were adjusted for multiple comparison using the Benjamini-
Hochberg correction method. Combined p-values were further filtered (p < 0.05 and
logFC < 0 for downregulated genes or logFC > 0 for upregulated genes).
3.2.4 Analysis of baseline transcriptomic signatures
Baseline transcriptomic signatures were defined for the 5 major clones in 4T1 WILDseq
tumours (clone 238, 350, 473, 679, and 684) using the vehicle datasets: 9 control,
vehicle-treated animals administered either 10% DMSO in 10% beta-cyclodextrin for 5
days/week, 12.5% ethanol mixed with 12.5% Kolliphor diluted in saline for 3 days/week,
or 12.5% DMSO in 0.5% sodium carboxymethyl cellulose for 5 days/week. Each clone
was required to be represented by at least 20 cells in each sample to compare its gene
expression to that of all WILDseq barcode assigned tumour cells. Comparisons were
performed at gene level using Seurat or at the geneset level using AUCell. P-values of
each sample were combined using the Fisher’s method.
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To test our approach, we applied WILDseq to study the response of our 4T1 mammary
carcinoma model to classic taxane-based chemotherapy and a first-in-class small-
molecule inhibitor of BET bromodomains JQ1. We implanted approximately 300
WILDseq barcoded clones into immunocompetent mice (Figure 3.1a).
Figure 3.1 WILDseq pipeline in vivo for docetaxel and JQ1 treatment. a| Schematic
illustration of WILDseq experimental workflow. b| Conditions of drugs were optimized to
initially reduce tumour burden, but eventually results in tumour relapse and resistance to
therapy. Drug treatment was started seven days post tumour initiation. Docetaxel was
given three times per week at 12.5 mg/kg for a total time span of two weeks, while JQ1 was
administered five times per week at 75 mg/kg until human endpoint (n=3 per condition).
Specifically, we stabilized our three parental 250 cell populations in culture, sorted
for WILDseq barcode expressing cells based on their zsGreen expression and pooled
the three populations at equal ratios immediately before implantation to increase
clonal competition in vivo. When tumours were palpable after one week, three mice
were treated with either 12.5 mg/kg docetaxel for a total of two weeks or 75 mg/kg
JQ1 (5 days on 2 days o ) until humane end-point (Figure 3.1b). Control animals
(n=9) were treated with vehicle formulations and tumours were collected at humane
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end-point after 21 days. Whilst both treatments initially reduced tumour burden, the
tumour ultimately overcame therapy and returned, indicative of selection and expansion
of treatment-resistant clones. Tumour samples were dissociated, live-dead sorted to
exclude debris and dead cells, and finally processed for single-cell RNA sequencing to
analyse tumour composition. To increase the barcode detection, we prepared a separate
barcode enrichment library from the pooled, amplified cDNA which was spiked into
the transcriptomic library.
Figure 3.2 WILDseq applied to study clonal dynamics under drug treatment in
vivo. a| UMAP representation of 4T1 WILDseq tumours generated by injecting the 4T1
WILDseq pool into the mammary fatpad of Balb/C mice. WILDseq barcode expression is
highlighted in red. b| UMAP representation of WILDseq experiments clustered by treatment
(VEH = all 9 vehicle treated samples) Three independent experiments were performed each
involving injection into three separate host animals (docetaxel = 3 animals, JQ1 = 3 animals,
Vehicle = 9 animals). Five major in vivo clones are highlighted in colours and other WILDseq
barcode assigned cells are shown in dark grey.
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In total, 64,426 single-cell transcriptomes were captured and resolved in 20 clusters
of transcriptionally distinct cells including tumour cells as well as cells from the tumour
microenvironment (Figure 3.2a). Visualization of WILDseq barcode expression was
highly specific for tumour cell clusters as expected. We analysed the cell transcrip-
tomes using the R package Seurat, including quality control, pre-processing, cell-cycle
regression and the SCTransform based normalisation (Hao et al., 2021).
In order to fully characterise our 4T1 WILDseq pool, we compared the clonal
distribution and gene expression profiles in vitro versus in vivo (Figure 3.3). We
observed no correlation (R2= 0.004816, p-value = n.s.) between initial (in vitro) and
final (in vivo) clonal abundance, suggesting that clone-intrinsic features conferring
greater fitness in vitro do not necessarily translate in a survival benefit in the in vivo
environment (Figure 3.3a).
Despite initially implanting ≥ 132 distinct clones, we only detected ≥ 69 clones in
vivo, suggesting that only a subpopulation of cells were competent for engraftment and
survival in vivo. While the in vitro pool was mostly dominated by two clones, 132 and
264, we observed five major clones in vivo: 238, 350, 473, 679 and 684. Downstream
analysis in the tumour was focused on the characteristics of the five major clones in
vivo.
When we compared gene expression signatures in vitro versus in vivo, we noticed
great variation in the clonal gene expression profiles (Figure 3.3b). Most clones
change dramatically with the setting and thus, are weakly correlated. In contrast,
clone 679 and 684 exhibit more robust gene expression signatures across conditions
reflected in a higher correlation coe cient. While clone 679 and 684 appear to have
intrinsic mechanisms that define their gene expression patterns, most clonal signatures
seem to be determined by external factors highlighting the importance to study clonal
dynamics in vivo with an intact immune environment.
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Figure 3.3 Comparing WILDseq pool in vitro versus in vivo. a| Clonal representation
of WILDseq pool in vitro versus in vivo. (n = 1 for in vitro cultured cells; n = 9 for in vivo
vehicle samples) b| Correlation of clonal gene expression signatures in vitro versus in vivo.
Transcriptomic profile of each clone was compared to all other clones combined to generate an
in vitro or in vivo clonal signature (logFC per gene) and illustrated as the pearson correlation
coe cient for each clone in vitro versus in vivo.
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3.3.1 Validation of WILDseq in a the triple-negative breast
cancer cell line D2A1-m2
To validate our approach in a second cell model, we selected the triple-negative breast
cancer cell line D2A1-m2. We infected D2A1-m2 cells at a low MOI allowing only
one WILDseq barcode per cell, followed by generating the D2A1-m2 WILDseq pool.
Similarly to the 4T1 WILDseq pool, the D2A1-m2 WILDseq pool consisted of three 250
cell populations which were kept separately until pooling in equal ratios immediately
before the tumour transplantation. We injected 60,000 D2A1-m2 WILDseq cells into
the fourth mammary fat-pad of Balb/C mice and tumours were collected at human
endpoint after 21 days. Tumours were processed into single cells, sorted for live-dead
cells to get rid of debris and submitted for analysis via scRNA-seq.
Figure 3.4 WILDseq characterisation of D2A1 tumours. a| UMAP representation of
D2A1-m2 WILDseq tumour highlighting the seven major WILDseq expressing clones. (n = 2
animals) b| Relative clonal abundance in D2A1-m2 WILDseq tumour. Individual clones are
highlighted in di erent colours. Clones that are present at levels below 1% are illustrated
together. In total, 89 di erent clones were observed across two independent samples with 9
clones contributing more than 70% to the total number of clones detected in the tumour.
(Mean±SEM)
We visualised the 7890 transcriptomes using the UMAP plot (Figure 3.4a). This
revealed great di erences in the tumour composition. In contrast to 4T1 WILDseq
48 Investigating therapeutic response using WILDseq in breast cancer
tumours, D2A1-m2 WILDseq tumours mostly consists of tumour cells and only ≥16%
were assigned to cells of the tumour microevironment. We next integrated the clonal
assignment of the WILDseq barcode into the transcriptomic data: from the 3127
cells passing the threshold to support clone calling, we identified 89 unique clones
on the basis of unique WILDseq barcodes (Figure 3.4b). This suggests that our
lentiviral-labeling approach can be deployed in any organism or in vitro culture system
that is susceptible to viral transduction to simultaneously profile transcriptomic and
clonal identity at single-cell resolution.
3.3.2 Characterising baseline signatures of major clones in
vivo
By analysing the transcriptome of these clones, we sought to comprehensively identify
inherent transcriptional programs associated with drug sensitivity and resistance. We,
therefore, performed di erential expression analysis on the five most abundant clones
in vivo using AUCell, an R tool for identifying gene signatures in scRNA-seq data. In
detail, AUCell calculates the area under the recovery curve (AUC) across each single
cell transcriptome to then determine whether a critical subset of the input geneset is
enriched in the cell. Genes are ranked from highest to lowest value for each cell using
the gene expression matrix from scRNA-seq dataset. Genes with the same expression
value are randomly sorted. Based on the AUC, AUCell measures the relative biological
activity of the input geneset in a given cell by estimating the proportion of genes in
the input geneset and their relative expression level compared to other genes.
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Figure 3.5 Characterisation of basal transcriptomic signatures of major clones in
vivo. Pathway analysis of most abundant clones in vivo in nine vehicle samples using AUCell
and 3801 input genesets. 67 genesets are highlighted and selected for their consistent and
statistically significant enrichment in a specific clone across tumours. AUCell score of each
clone was individually compared on per sample basis to all other clones with an assigned
WILDseq barcode. The mean  AUCell score across all tumour vehicle samples are plotted.
A minimum of at least 20 cells of the clone of interest was set as a threshold for a vehicle
sample to be included in the analysis (Clone 238: n = 5; Clone 350: n = 7; Clone 473: n =
7; Clone 679: n = 6; Clone 684: n = 8).
To define baseline signatures of our major clones in vivo (clone 238, 350, 473, 679,
and 684), we computationally extracted all tumour cells expressing a WILDseq barcode
in each vehicle sample and compared each clone individually versus the rest of the
tumour to identify which gene sets were enriched or depleted (Figure 3.5). Overall,
we analysed the expression of 3801 genesets with identifying 738 genesets as being
significantly enriched and 764 genesets as being significantly depleted across our five
major clones. To define consistently enriched or depleted genesets, we first calculated a
p-value on a per cell basis and determined the combined p-value on a per-sample basis
for each geneset. We then searched for genesets that represented the same phenotypic
functional process and defined signatures for the five major clones in vivo. Each of
the clones showed distinct gene programs that were specific to clones and for their
regulation of functional pathways. For example, clone 473 was highly enriched in DNA
damage-related genesets at base line. We, in particular, observed several ATM-related
pathways which are activated upon DNA double-strand breaks. In contrast, clone
679 exhibited a distinct hypoxia signature, including upregulation of HIF and VEGF
pathways, which might have been triggered by its tumour microenvironment in vivo or
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represents an intrinsic mechanism. Moreover, clone 238 and 684 upregulated epithelial
genesets suggesting a more epithelial, basal phenotype as opposed to clone 679 that
exhibited more a mesenchymal phenotype with high levels of Twist1. This supports
the idea that di erences in 4T1 clones may be defined based their position on the
epithelial-to-mesenchymal (EMT) axis and is in agreement with previous work that
further identified the master regulator Twist, a repressor of E-cadherin expression, as
being highly expressed and relevant for EMT in 4T1 cells (Yang et al., 2004).
3.3.3 Defining resistance and sensitivity signatures to
docetaxel
A key advantage of our lineage tracer is in unambiguously cross-referencing tumour cells
from the same lineage between samples and thus, allowing us to untangle transcriptional
signatures of clonal subpopulations in treated versus control samples. As a proof-of-
principle experiment, we examined the sensitivity of our 4T1 breast cancer model to
the chemotherapeutic docetaxel, known to cause growth arrest and cell death in cancer
cells by inhibiting depolarisation of microtubules. After profiling 22,771 transcriptomes
by scRNA-seq, we integrated the WILDseq barcodes into the single-cell landscape.
Around 30% of the sequenced tumour cells were robustly assigned with a WILDseq
barcode (Figure 3.6a).
To understand what defines sensitivity and resistance mechanisms to docetaxel
treatment, we pursued two analysis strategies:
1. Identification of di erentially expressed genesets was performed using AUCell,
and
2. Individual marker genes of resistance and sensitivity were identified using the
FindMarker function in the R package Seurat.
In both cases, we compared each clone individually against all tumour cells with an
assigned WILDseq barcode in each vehicle sample and calculated a combined p-value
across samples to identify robust markers for resistance and sensitivity (p-value < 0.05
and   < 0 or   > 0 in every comparison). Notably, we only included vehicle samples
that contained at least 20 cells of the clone of interest for the analysis.
To identify sensitive and resistance clones to docetaxel, we first computationally
extracted WILDseq barcode expressing cells from the tumour cell clusters and examined
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clonal proportions in vehicle and treated samples. We then identified clone 238 as a
docetaxel sensitive clone, while clone 679 dramatically increased upon treatment and
therefore, marks an example of a resistant clone Figure 3.6b.
Figure 3.6 Characterising clonal dynamics in 4T1 WILDseq tumours to docetaxel
treatment. a| UMAP representation of docetaxel-treated and control samples highlighting
major WILDseq clones in colour and other clones with assigned WILDseq barcode in dark
grey. b| Clonal proportions in docetaxel-treated versus control samples. Tumours cells were
assigned a clonal lineage based on their WILDseq barcode expression. Threshold for clones
shown was at least 20 cells across three animals in at least one condition. Clone 679 represents
a resistant clone, while clone 238 was sensitive to docetaxel treatment. (Mean±SEM)
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We first focused on the geneset analysis and compared the baseline signatures of
clone 679 and clone 238. Clone 679 showed high levels of hypoxia-related pathways
which have been associated with taxane resistance in the past. Many chemotherapeutic
drugs share a similar mechanism of action eventually resulting in increased DNA
damage. Resistance mechanisms, such as drug e ux pumps or increased levels of
hypoxia, end up conferring resistance across various cytotoxic drugs. Interestingly,
clone 679 showed upregulation and downregulation of genesets associated with cisplatin-
resistance, thus further supporting our findings (Figure 3.7a). In contrast, clone 238
exhibited a more epithelial-basal like phenotype suggested by the downregulation of
epithelial-to-mesenchymal (EMT) and epithelial-related gene sets and an upregulation
of basal cytokeratins (Figure 3.7a,b).
Figure 3.7 Clonal transcriptomic signatures of docetaxel resistance and sensitivity.
a| Geneset enrichment analysis of resistant clone 679 using AUCell. AUCell scores per cell
were determined based on six control animal with at least 20 cells for clone 679. Geneset
AUCell scores of clone 679 were compared to all other assigned clones within each tumour
using a Wilcoxon rank sum test and combined p-values were calculated using the Fisher’s
method. The  AUCell score was determined for each geneset comparing the median AUCell
score of clone 679 to all other clones. The mean of this score is illustrated with the strongest
and most significant positive and negative genesets annotated (gold and blue, respectively).
Two independent genesets associated with cisplatin resistance were upregulated (red). b|
Geneset enrichment analysis of sensitive clone 238 using AUCell. Analysis was performed as
in a using data from five vehicle control animals for which at least 20 cells were identified for
clone 238. Significantly changing genesets are highlighted.
Next, we performed the gene level analysis to identify specific marker genes associ-
ated with docetaxel resistance and sensitivity using Seurat. The gene level signatures
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were negatively correlated between clone 679 and clone 238. Genes enriched in clone
679, including Twist1, Mgst1 and Mgst2, represented markers for docetaxel resistance.
Reciprocally, genes upregulated in clone 238, including Krt14/17, Cldn3/4, and Epcam
were associated with docetaxel sensitivity (Figure 3.8). As expected, di erentially
expressed genes between clone 679 and clone 238 corresponded to signatures of ep-
ithelial versus mesenchymal-like phenotypes known to result in such a response to
chemotherapy treatment.
Figure 3.8 Correlation of di erentially expressed genes in clone 679 and clone 238
versus all other clones. Gene expression was compared between clone 679/clone 238 and
the rest of the assigned tumour cells within each control animal with at least 20 cells of
the clone of interest. The mean logFC across animals for each gene is plotted (Pearson
correlation, R=-0.398, p < 2.2x10≠16). Genes highlighted in gold are markers for docetaxel
resistance (high in clone 679) and genes highlighted are markers for docetaxel sensitivity
(high in clone 238).
Next, we confirmed our results in gene expression data of patients using ROC-
plotter (Fekete and Gy r y, 2019). Strikingly, the expression of our resistance and
sensitivity signatures correlated with the outcome of patients treated with taxane-based
chemotherapy (Figure 3.9). Patients that showed pathological complete response,
defined as no evidence of residual disease post therapy, were high in genes associated
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with our sensitive clone 238 and low in genes associated with the resistant clone 679.
In contrast, non-responding patients were high in genes associated with the resistant
clone. Together, these results demonstrated the power of our WILDseq pipeline in
identifying signatures of resistance and sensitivity and highlighted the relevance of our
findings as predictors for patient response to chemotherapy.
Figure 3.9 Transcriptomic signatures of docetaxel resistance and sensitivity in
patient treated with taxane-based chemotherapy. Data set of breast cancer patients
was retrieved from ROCplot.org (Fekete and Gy r y, 2019) and consists of transcriptomic
data of 3,104 treated breast cancer patient. Patients with response to docetaxel treatment
showed upregulation in genes associated with the sensitive clone 238, while non-responding
patients had high expression of genes associated with the resistant clone 679.
3.3.4 Defining resistance and sensitivity signatures to JQ1
Accumulating evidence suggests that a small subpopulation of cancer cells exhibiting
acquired drug resistance do not necessarily require a stable heritable genetic alteration.
Such findings suggest a reversible "drug-tolerant" state initiating through non-genetic
mechanisms, such as epigenetic regulations. To this end, we wished to understand the
anti-proliferative e cacy and the ensuing resistance to epigenetic cancer therapy with
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JQ1. JQ1 is a selective small-molecule inhibitor of BET bromodomains that utilizes
acetyl-lysine-competitive binding to displace BET bromodomains from chromatin,
resulting in transcriptional changes and anti-proliferative e ects (Delmore et al., 2011).
Figure 3.10 Characterisation of clonal dynamics in JQ1-treated WILDseq tumours.
a| UMAP representation of JQ1-treated and control samples highlighting major WILDseq
clones in colour and other assigned clones in dark grey. (n = 3 per condition) b| Clonal
proportions in JQ1-treated versus control samples. Clones with at least 20 cells across 3
animals in at least one condition are shown. Clone 264 represents a resistant clone, while
clone 473 was sensitive to JQ1 treatment. (Mean±SEM)
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Single-cell profiling of JQ1 and vehicle treated tumours resulted in a total of 28,768
transcriptomes with nearly 50% of tumour cells expressing a WILDseq barcode (Figure
3.10a). Analysis of clonal distributions between conditions marked clone 264 as a
resistant clone, while clone 473 represented an example of a sensitive clone (Figure
3.10b).
Figure 3.11 Baseline signature of clone 473 primes it for JQ1 sensitivity. Geneset
enrichment analysis of resistant clone 473 using AUCell. AUCell scores per cell were
determined based on seven control animal with at least 20 cells for clone 473. Geneset
AUCell scores of clone 473 were compared to all other assigned clones within each tumour
using a Wilcoxon rank sum test and combined p-values were calculated using the Fisher’s
method. The  AUCell score was determined for each geneset comparing the median AUCell
score of clone 473 to all other clones. The mean of this score is illustrated and significantly
upregulated epithelial/EMT-related genesets (pink) as well as high levels of DNA damage
response genesets (gold) are highlighted.
In order to understand what determines JQ1 sensitivity, we examined the baseline
signature of clone 473 and found an enrichment of DNA damage repair pathways,
including several ATM-mediated pathways, already in the absence of treatment (Figure
3.11). Clone 473 also exhibited high levels of epithelial and EMT-related genesets
suggesting a more epithelial-basal phenotype.
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Figure 3.12 Global downregulation of MYC targets in JQ1-treated tumour. a|
MYC target gene expression (in total 130 target genes in geneset) in vehicle versus JQ1-
treated samples. AUCell scores per tumour cell in vehicle versus JQ1 treated animals is
plotted. LogFC from the median AUCell score per condition is -0.038 and significance was
tested using Wilcoxon Rank Sum Test. JQ1 treatment resulted in a downregulation of MYC
target genes across all samples. b| Clonal response to JQ1 treatment on MYC target gene
expression. AUCell score per cell for assigned tumour cells in the most abundant clones
are illustrated for JQ1-treated and vehicle samples. LogFC of the median AUCell score per
condition is plotted and significance was tested using Wilcoxon Rank Sum Test. Notable,
detailed analysis on clonal level revealed dramatic suppression of MYC targets in clone
473 compared to other clones which exhibited a moderate inhibition. (n = 3 animals per
condition)
Various studies have linked DNA damage as well as JQ1-treatment with MYC
inhibition (Cannell et al., 2010; Porter et al., 2017). Further analysis of MYC -target
gene expression revealed a global but modest downregulation of MYC target genes
in JQ1-treated tumours (Figure 3.12a). Interestingly, analysis of MYC -target gene
expression on clonal level revealed dramatic suppression of MYC -target genes in
clone 473 specifically compared to the other major clones which showed a moderate
downregulation of MYC target genes (Figure 3.12b). This observation suggested a
combined e ect of cells that have already been intrinsically primed to MYC suppression
based on high levels of DNA damage which is then further increased by JQ1-induced
DNA damage mediating profound MYC suppression (Delmore et al., 2011).
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Figure 3.13 JQ1 treatment results in specific depletion of CD8+ T-cells in breast
cancer tumours. a| UMAP representation of T-cell cluster highlighting specific depletion
of CD8+ T-cells in JQ1-treated samples. T-cell cluster was extracted from JQ1 dataset and
reclustered. b| T-cell subcluster identity was assigned based on gene expression of established
markers. c| Relative proportions of T-cell subtypes in vehicle versus JQ1-treated samples
(Mean ± SEM; n = 3 animals per condition). d| Relative proportions of clones in vitro, in
vehicle or JQ1-treated samples. Although clone 264 and 439 are dominant in vitro, they are
only detected in JQ1 treated samples.(Mean ± SEM)
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Finally, we focused on unravelling the resistance mechanisms in clone 264. Despite
being a dominant clone in the in vitro pool, clone 264 was only detected in JQ1-treated
tumours in vivo, suggesting it is selected against in vivo under normal conditions.
Moreover, we observed a specific depletion of T-cells upon JQ1 treatment which might
be linked to the appearance of clone 264. Reclustering of the T-cell population and
identifying T-cell subtypes based on gene expression of established markers revealed a
specific depletion of CD8+ T-cells and an increase of CD4+ T cells in JQ1-treated
samples (Figure 3.13a-c). The decrease in CD8+ T-cells reciprocally coincided with
the appearance of clone 264 in the tumour (Figure 3.13d). Clone 350, 684, 238
and 679 were minor populations in vitro, but showed comparable levels in vivo in
both conditions. In contrast, clone 439 and in particular clone 264 showed a higher
representation in vivo with clone 264 being the dominant clone in the in vitro pool,
but are only detected upon JQ1 treatment. Thus, we hypothesised that JQ1 treatment
may result in transcriptional changes that prevent CD8+ T-cells from being recruited
to the tumour resulting in an "immune cold" tumour that allows clone 264 to survive
and expand. Di erent strategies have been reported that describe mechanisms of
how tumour cells might prevent T-cell infiltration. Indeed, di erential expression
analysis of vehicle versus JQ1-treated tumours revealed global JQ1-dependent gene
expression changes (Figure 3.14a). Many of the genes globally downregulated were
part of the major histocompatibility complex (MHC) class I antigen presentation
pathway, including TAP peptide transporters, proteasomal components and the beta-2
microglobulin subunit of the major histocompatibility class I complex (B2m) (Figure
3.14a). Our pathway analysis further agreed with our gene level analysis highlighting
a significant downregulation of antigen representation-related pathways in JQ1-treated
tumours (Figure 3.14b). These findings suggested a loss of antigen presentation as a
possible mechanism that would clearly impact the T-cell response to a tumour.
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Figure 3.14 Global JQ1-dependent gene expression changes. a| Heatmap of global
JQ1-dependent gene expression changes. Gene expression of the five most abundant clones
is illustrated. Analysis was performed with 1000 randomly selected cells of each clone per
condition. Genes shown were significantly downregulated across all five clones in JQ1-treated
animals versus vehicle animals. b| JQ1-dependent downregulation of antigen representation
pathways. The median AUCell score per animal per clone is illustrated using tumours with
at least 20 cells assigned to the clone of interest. Genesets were significantly downregulated
across the four most abundant clones in JQ1-treated animals versus vehicle animals. P-values
shown were calculated using a student t-test to compare 11 vehicle treated clones and 11 JQ1
treated clones.
One of the genes we were particular interested in was B2m which was heterogeneously
expressed across the clones in vitro (Figure 3.15a). Notably, clone 439 and 264 showed
the highest levels among all clones in vitro. We next performed pairwise di erential
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expression analysis of the most abundant clones in vivo comparing their expression in
the vehicle tumours versus the JQ1-treated tumours.
Figure 3.15 JQ1 resistance correlates with —-2-microglobulin (B2m) expression. a|
B2m expression per clone in vitro or b| in vivo for most abundant clones in JQ1-treated
tumours. p-values were determined using Wilcoxon rank sum test.
Consistently, clone 439 and 264 showed the highest expression levels of B2m
in the vehicle as well as JQ1-treated samples. However, we also observed a global
downregulation of B2m in JQ1-treated tumours across all clones. Thus, we hypothesised
that the higher levels of the antigen representation machinery in clone 264 and 439
might prevent these clones from surviving under normal conditions in vivo due to
their clearance through T-cells. In the presence of JQ1 treatment, however, antigen
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representation is downregulated resulting in a cold tumour and allowing clones that
would normally not be observed to grow out.
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3.3.5 Discussion
Understanding intratumour heterogeneity, which underpins tumour evolution and
chemoresistance, is a key challenge in cancer medicine. By applying our WILDseq
platform to a syngeneic, heterogeneous mouse model of breast cancer, we tackled
this problem and unravelled meaningful insights into the evolution of drug resistance
through simultaneous single cell profiling of clonal lineage and gene expression. Among
these key insights were the characterisation of clonally distinct transcriptomic signa-
tures associated with di erential responses to cytotoxic therapy, the identification of
predictive biomarkers for docetaxel treatment to stratify breast cancer patients, and
novel immune cell related resistance mechanism to JQ1 treatment.
We characterised distinct intrinsic gene expression programs in vivo linked with
clonal sensitivity or resistance to treatment. Interestingly, we observed great variation
of clonal transcriptomic profiles in vitro and in vivo implying a high dependency on ex-
ternal factors, including the tumour microenvironment. One of the strongest signatures
upregulated upon docetaxel treatment in the resistant phenotype was HIF-1 regulated
gene expression program induced by hypoxia. This is consistent with other studies that
have reported the involvement of hypoxia in chemotherapeutic resistance in many cell
lines through di erent mechanisms, including cell cycle arrest (Huang et al., 2010; Pucci
et al., 2018), upregulation of drug e ux pumps (Samanta et al., 2014) or inhibition
of apoptosis (Flamant et al., 2010). Moreover, we defined predictive biomarkers for
docetaxel resistance (Mgst1, Mgst2 and Twist1 ) and docetaxel sensitivity (Krt7 and
Epcam). Mgst1 and Mgst2 belong to the glutathione-S-transferase (GST) enzyme
family that have been implicated in the development of drug resistance through their
role in direct detoxification of oxidative stress as well as acting as a regulation of the
MAP kinase pathway (Townsend and Tew, 2003). We speculate that the hypoxia
signature at baseline in the resistant cells increased the levels of glutathione metabolism
in order to regulate and detoxify reactive oxygen species (ROS) which in turn results
in a protection mechanism from docetaxel induced damage.
Another marker for docetaxel resistance was Twist1, a master regulator of the
epithelial-to-mesenchymal transition (EMT), a process through which cells adopt mi-
gratory and invasive behavior. Reprogramming of tumour cells through EMT has long
been associated with chemoresistance (Bhang et al., 2015; Polyak and Weinberg, 2009).
Moreover, enforced expression of Twist in breast cancer cell lines is su cient to induce
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an EMT and loss of E-cadherin expression suggesting that Twist might contribute to a
more aggressive phenotype of invasion and metastasis (Yang et al., 2004). Conversely,
chemosensitive cells expressed high levels of the canonical epithelial markers Krt7 and
Epcam representing the other end of the EMT spectrum. Gene expression di erences
in the 4T1 model are most likely to be largely attributable to their position on the
EMT spectrum. Taken together, our work suggests that docetaxel resistance is me-
diated through intrinsic mechanisms that are associated with a more mesenchymal
phenotype and ability to cope with high levels of oxidative stress, while cells with a
more epithelial-basal phenotype do not survive treatment. Finally, we successfully
confirmed our predictive signatures in breast cancer patient data highlighting the
clinical relevance of our findings.
To our knowledge, this is the first report of using a syngeneic cancer model in an
intact immune system to study the complex interplay between intrinsic clonal properties
and their external factors, including the microenvironment, and how they cooperate to
drive therapy resistance. One group of potential therapeutics in triple-negative breast
cancer are BET bromodomain inhibitors, but acquired resistance to these inhibitors
limit their potential in clinical use (Shu et al., 2016). Using WILD-Seq we found that
cells sensitive to JQ1 were intrinsically primed with high levels of DNA damage, while
JQ1 resistance was driven by micro-environmental factors associated with specific
depletion of CD8+ T-cells. While we observed modest suppression of MYC signaling
across clones, we observed a dramatic downregulation of MYC pathways specifically
in JQ1 sensitive cells. We hypothesize that MYC target gene suppression might be a
result of a combination of high levels of baseline DNA damage through double-strand
breaks (Porter et al., 2017) and additional DNA damage induced by JQ1 treatment
(Delmore et al., 2011), that synergise to repress MYC and kill cells. The nature of JQ1
resistance was mostly driven by micro-environmental factors rather than an intrinsic,
primed state, such as for JQ1 sensitivity. The specific depletion of CD8+ T-cells
coincided with a global decrease in antigen presentation after JQ1 treatment and the
appearance of clones which have been only detected in vitro. These results suggest
that decrease of antigen presentation in tumour cells results in alterations of T-cells
and eventually lead in the depletion of CD8+ T cells, thereby allowing clones that
usually are removed by the immune system to survive and expand. Future studies will
focus on validating our proposed resistance mechanism by studying clonal dynamics in
the absence of an intact immune system. This should allow clones that are usually
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cleared out by the immune system to survive and be captured on the WILDseq platform.
These JQ1 data perfectly exemplifies a key advantage of WILDseq using a syngeneic
mouse model with an intact immune system to capture the complex interplay between
the tumor micro-environment and the clonal architecture and how these are remodelled
by therapeutic intervention. Alternative approaches, such as CRISPR-based systems,
will face certain di culties in using syngeneic cancer models due to the need of
delivering multiple components and thereby increasing the risk of immunogenicity or
heavy silencing of barcode/vector expression resulting in clonal dropouts. Additionally,






Due to the experimental demands of this project, this chapter would not be in my
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presented in this chapter has been carried out by me. The CloneSTAR vector was
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CloneSTAR clones was performed by Dr. Kirsty Sawicka. Sequencing was performed
by the Genomics Core Facility. The analysis pipeline for decoding STARmap cycles
was performed in collaboration with Eduardo Gonzales Solares from the Astronomy
Department of the University of Cambridge.
4.1 Introduction
Single cell genomics has proven to be a powerful tool for transcriptome-wide profiling of
individual cells, providing information on cell types, developmental relations and gene
programs. However since this method requires a dissociated single cell suspension as
the starting material, it by necessity destroys information on the spatial localization of
cells within the native tissue and their proximities to each other. Considering that cell
signaling operates from 0 to 200 µm, such spatial information is crucial to understand
intercellular interactions and the spatial organisation of normal and diseased tissue
(Longo et al., 2021). Spatial transcriptomic approaches address this challenge by
physically measuring gene expression in intact tissue with the potential to achieve
single cell or even subcellular resolution. Integrating scRNA-seq data and spatial
transcriptomic measurements, has the potential to map phenotypic features into a
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structural context. Currently, spatial transcriptomic tools are limited in their resolution
and number of transcripts they can detect simultaneously in precisely localized single
cells in tissues. However, they can elucidate niches enriched for distinct gene sets
and cell types allowing cell subpopulations to be mapped into tissue neighbourhoods.
When used in combination, scRNA-seq and spatial transcriptomics allow mapping of
transcriptionally characterised single-cells to their spatial localization in the native
tissue.
We apply STARmap, a novel sequencing-based technology for targeted 3D in situ
transcriptomics, for the first time to tumour tissue. We demonstrate how scRNA-seq
data can be used to guide probe design for spatial analysis of tumour heterogeneity
and microenvironment and explore the possibility of incorporating lineage tracing
via the WILDseq barcoding approach into our spatial transcriptomics method to
simultaneously detect the spatial distribution of clones together with transcripts of
interest.
Figure 4.1 Schematic illustration of STARmap protocol. After tissue section or cells
are prepared, custom SNAIL probes hybridize to intracellular mRNAs resulting in ligation of
the padlock probe and followed by enzymatic amplification using rolling-circle-amplification
(RCA) and amino-modified nucleotides. cDNA amplicons are then coupled to an acrylic acid
N-hydroxysuccinimide (NHS) moiety allowing the copolymerization with acrylamid to form a
hydrogel network, followed by clearance of unbound lipids and proteins. Each SNAIL probes
contains a unique five nucleotide barcode which is assigned to a specific gene. Using in situ
sequencing with two-base encoding for error correction (SEDAL) the barcode is read-out
over several imaging cycles. Each imaging cycle is followed by probe stripping using 60%
formamide before the next cycle begins. Adapter from Wang et al. (2018).
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STARmap is a targeted in situ technology combining in situ sequencing and in situ
hybridisation with the ability to measure up to 1,000 genes in tissue sections (Figure
4.1) (Wang et al., 2018). The method relies on the padlock probe system SNAIL
(specific amplification of nucleic acids via intramolecular ligation) consisting of a primer
and padlock probe pair to detect intracellular mRNA. Each padlock probe contains
a five-base barcode designed as a gene-specific identifier. Notably, both probes are
required to bind next to each other in order to initiate padlock probe circularization and
rolling-circle amplification (RCA). Similar to other imaging-based methods, hydrogel-
tissue chemistry is then used to embed the cDNA nanoball (amplicon) into a hydrogel
network allowing to remove proteins and lipids for enhanced transparency. To reduce
the error rates generated from single base readout, in situ sequencing of DNA amplicons
is performed using SEDAL (sequencing with error-reduction by dynamic annealing
and ligation), the sequencing-by-ligation method devised for STARmap. SEDAL relies
on two kind of probes: reading probes to decode bases and fluorescent probes to
convert sequence information into fluorescence signals. With each cycle the number of
degenerated bases of the reading probe incrementally increase. Only if both probes are
perfectly complementary to the DNA template, a stable product with high melting
temperature can be formed via ligation, allowing later imaging after washes to remove
unligated probes. Using 60% formamide probes are stripped after each imaging cycle
for the next cycle to begin. To enable simultaneous detection of the clonal identity
and transcriptomic profiles within the native tissue, we developed CloneSTAR, an
inheritable barcoding system detectable with STARmap and scRNA-seq. We leverage
scRNA-seq data to define transcriptional profiles corresponding to specific cell identities
which we in turn used to design probe sets for STARmap. First, we established the
STARmap protocol in breast cancer cells and tissue followed by testing our CloneSTAR
method.
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4.2 Material and Methods
4.2.1 Designing and cloning 40-mer barcodes for CloneSTAR
We generated 40-mer barcodes using the python software package FreeBarcodes
(Hawkins et al., 2018). Barcodes were designed with a distance of 9 and the fol-
lowing experimental parameters: minimal GC content 55%, maximal GC content 70%,
maximal homopolymer runs of 2 nt, and length 20 nt. The resulting barcodes were
further filtered for barcodes with a melting temperature (Tm) of 60 ¶C ± 2 ¶C resulting
in a final pool of potential barcodes. To create 40-mer barcodes, we combined two
20-mer barcode sequences with one nucleotide in between and added common flanking
regions that were homologous to the desired plasmid insertion site (Integrated DNA
Technologies). The fragments were then introduced into the SwaI digested pHSW8
backbone using PCR and Gibson Assembly (NEB), followed by bacterial transformation
and maxi-prep extraction of the plasmid DNA.
4.2.2 Creating barcoded clones for CloneSTAR validation ex-
periments
The clonal cell lines 4T1-E, 4T1-F, 4T1-G, 4T1-J, 4T1-M, 4T1-R, and 4T1-T (Wagen-
blast et al., 2015) were cultured in DMEM high glucose and pyruvate supplemented
with 10% FBS and 5% penicillin–streptomycin (Gibco). Each clonal line was infected
with a lentiviral barcode and positive cells were sorted using the FACSAria IIU cell
sorter (BD Biosciences). The barcode of each individual clonal cell line was confirmed
by reverse transcription of expressed barcodes and Sanger sequencing.
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4.2.3 Slide coating for cell and tissue experiments
Micro coverglasses or glass-bottom chambers were immersed with methacryloxypropy-
ltrimethoxysilane (Bind-Silane; GE Healthcare) for 5 mins and washed in 100% ethanol.
For tissue slices, glass surfaces were further treated with poly-L-lysine solution (Sigma
Aldrich) for 5 mins and left to dry overnight. Prior to plating cells, glass surfaces were
sterilized using 70% ethanol and washed three times with PBS.
4.2.4 Sample preparation
Cells were grown on pre-treated coverslips (#13 mm) or glass-bottom 24-well plates for
48hrs. After fixing cells in 4% PFA, cells were permeabilised in pre-chilled methanol
at -20 ¶C for 10 mins and then placed at -80 ¶C for 15 mins prior to hybridisation or
stored at -80 ¶C for up to one week. Breast tumour tissue samples were immediately
embedded in O.C.T, snap-frozen with isopentane and stored at -80 ¶C. Tissue was
cut into 16 µM slices and mounted on pre-treated glass-bottom slides. Tissue slides
were fixed with 4% PFA in PBS at room temperature for 10 mins, permeabilised with
methanol at -20 ¶C and then placed at -80 ¶C for 15 mins prior to hybridisation.
4.2.5 STARmap procedure for cells and tissue slices
Glass-bottom plates and coverslips in plate were equilibrated to room temperature,
washed with PBST-R (0.1% Tween-20 (Sigma-Aldrich), 0.1 U/µL SUPERaseIn (Invit-
rogen) in PBS) for at least 5 mins and pre-incubated with hybridisation bu er (2X
SSC, 10% formamide, 1% Tween-20, 20 mM RVC and 0.1 mg/mL salmon sperm DNA)
for 5 mins. SNAIL probes were dissolved at 200 µM in UltraPure DNAse/RNAse-free
distilled water (Invitrogen) and pooled to 25 µM each. Probe solution was prepared
by diluting 100 nM SNAIL probes in hybridisation bu er and added to the samples.
The hybridisation reaction was incubated at 40 ¶C in a humidified oven overnight.
Samples were then washed twice with PBST-R and once with 4X SSC/PBST-R for 20
mins at 37 ¶C in a humidified container. After rinsing the samples with PBST-R at
room temperature, samples were incubated for two hours with T4 DNA ligation mixture
(0.1 U/µL T4 DNA Ligase (Invitrogen), 1X Ligation bu er, 1X BSA (NEB) and 0.2
U/µL of SUPERase-In (Invitrogen)) at room temperature with gentle agitation. The
samples were washed twice with PBSTR and then incubated with the RCA reaction
mixture (0.1 U/µL Phi29 DNA polymerase (Invitrogen), 250 µM dNTP mix, 1X BSA,
20 µM 5-(3-aminsoallyl)-dUTP and 0.2 U/µL of SUPERase-In) at 30 ¶C for two hours.
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Following two washes in PBST-R, the samples were stored in PBST-R with 2 µL/mL
SUPERase-In overnight at 4 ¶C.
The next day, samples were washed with PBS and treated with 20 mM acrylic acid NHS
ester (Stock concentration: 300 mM dissolved in anhydrous DMSO) in PBS for 2 hrs at
room temperature. The samples were briefly washed twice with PBST and incubated
with monomer bu er (4% acrylamide and 0.2% bis-acrylamide in 2X SSC) for 30 mins
at room temperature. The monomer bu er was removed from the samples and the
polymerisation mix was added to the centre of the sample and immediately covered
with repel silane coated coverslips. The solution was then allowed to polymerise for 1
hr at room temperature. The coverslips were then gently removed and the samples
were washed twice in PBST prior to incubation with digestion bu er consisting of 0.2
mg/mL Proteinase K and 1% SDS in 2X SSC. The sample was digested for one hour
at 37 ¶C and then washed three times with PBST. The protocol was either continued
at this stage or the samples were stored in PBS at 4 ¶C overnight.
4.2.6 STARmap imaging and in situ sequencing
For single-gene/barcode detection, samples were incubated with a 19-nt fluorescent
oligo at a concentration of 500 nM in 1X SSC/PBST for 30 mins at room temperature,
followed by 3 washes with 10% formamide (Sigma Aldrich) in 2X SSC. Each sequencing
cycle started with a stripping process: two rounds of stripping were performed with
60% formamide and 0.1% Triton-X-100 for 10 mins at room temperature, followed by
three washes in PBST. The sample was then placed into the sequencing reaction (0.1
U/µL T4 DNA Ligase (Invitrogen), 1X T4 DNA ligase bu er, 1X BSA, 10 µM reading
probe and 5 µM fluorescent oligos) for 3 hrs at room temperature. The sample was
washed three times with 2X SSC and 10% formamide gently agitating and placed into
fresh bu er prior to imaging. DAPI staining was performed following manufacturer’s
instructions every second cycle for the purpose of image registration. Images were
acquired using Leica WLL SP8 confocal microscopy with a 405 diode, white light laser,
40x and 60x oil-immsersed objective (NA 1.3).
4.2.7 STARmap and CloneSTAR probe design
The appropriate transcript sequence per gene was selected from bulk RNA-seq data
from 4T1 cells. In cases of multiple isoform expression, probes were designed against a
shared sequence between expressed isoforms. Probes were designed using the program
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Picky 2.2 (Wang et al., 2018) by dividing each transcript into two halves and up to
five target sequences were identified for each half. Downstream analysis and sequence
selection was performed in R. Each target sequence is 40-46 nt in length and was split
into two oligos with a gap of 0-2 nt between probe sequences by selecting the pair with
the best melting temperature match. Sequences were further filtered for GC content,
repetitive sequences, closest non-target Tm and spacing along the transcript resulting
in four final probe pairs per transcript. CloneSTAR barcodes were targeted by a single
probe pair. Reading probes including six reading probes (R1 to R6) and twelve 2-base
encoding fluorescent probes labelled with either Alexa546, 596 or 647 were purchased
from IDT. For detection with a single probe, 19 nt detection probes (detect1) labelled
with either Alexa546, 596 or 647 were purchased from IDT.
4.2.8 Single-cell RNA sequencing and marker selection
Cell preparation for scRNA-seq Cells and tissue samples were prepared as de-
scribed in section 2.2.7.
Bioinformatic analysis Read alignment, generation of expression matrix and down-
stream analysis in Seurat was performed as described in section 2.2.10.
CloneSTAR barcode demultiplexing. Reads mapping to the CloneSTAR barcode
sequence were extracted from the processed and filtered BAM file produced by Cell
Ranger. The resulting BAM file was filtered for reads that show at least a 20 nt overlap
with the 40-mer CloneSTAR barcode and exactly mapped to the expected sequence.
Using a customised R script, only CloneSTAR barcode assignments supported by at
least 2 UMIs and 80% of the barcode sequences from the cell were included for down-
stream analysis. The final barcode list was added to the metadata of the corresponding
Seurat object for clone identification.
CloneSTAR marker selection. Cluster identity was assigned based on CloneSTAR
expression. Significantly enriched genes per clone were defined with a adjusted p value
< 0.05 and a log fold change > 0.1. Markers were selected from the resulting list
using the following selection criteria: (1) Significantly enriched in clone cluster;(2)
not significantly enriched in any other clone cluster; and (3) Log fold change > 0.3.
Universally expressed genes were selected based on their expression in >70% of cells
across all clusters and for not being significantly enriched in any cluster.
Tumour microenvironment marker selection. Significantly enriched genes per
cluster were determined with a log fold change > 0.25. Markers were selected based on
the intersect of significantly enriched genes and tumour microenvironment cell type
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In order to map the clonal composition of tumours in a spatial context, three possible
approaches can be used:
1. Detection of genetic clonality via DNAFISH or transcriptional start sites
2. Detection of expressed barcode transcripts through spatial transcriptomics or
3. Detection of distinct gene expression signatures assigned to clonal identities
Here, we focused on establishing the identification of clonal niches via an expressable
barcoding system in combination with STARmap. As an alternative, we explored the
option of defining gene expression signatures specific to distinct clones using scRNA-seq
to map clonal niches in tissue. We, therefore, leveraged our expressable barcoding
system as a ground-truth dataset.
4.3.1 Design of CloneSTAR vector and detecting of
CloneSTAR barcodes in vitro
To enable direct visualisation of clones and gene expression while preserving the spatial
context, we adapted our WILDseq technology and made it compatible with STARmap.
STARmap detection relies on detecting the transcript of interest using a pair of primer
and padlock probes. This approach is termed SNAIL, for specific amplification of
nucleic acids via intramolecular ligation. Each probe targets an area between 18-20 nu-
cleotides (nt) and only when both probes hybridise adjacent to each other on the same
transcript, the padlock probe can be circularised through ligation and amplified using
RCA. In order to make our WILDseq barcode compatible with the SNAIL method, we
designed the "CloneSTAR" barcode (Figure 4.2a). We replaced the WILDseq barcode
cassette with a 40-mer barcode sequence consisting of two unique 20 nt sequences
separated by one nucleotide allowing enough sequence space for SNAIL probes to bind.
Each barcode was detected with one specific pair of SNAIL probes in contrast to genes
which were detected using four probe pairs. Furthermore, we designed a single probe
complementary to each barcode DNA amplicon allowing barcode detection without
SEDAL. CloneSTAR barcodes are expressed in the 3’UTR of the zsGreen reporter
fluorophore (CloneSTAR transcript).
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We first set out a system with known transcriptomic di erences in order to test
CloneSTAR. We analysed bulk RNA sequencing data of 23 clonal lines derived from
the heterogeneous 4T1 breast cancer model, previously generated in our laboratory
and selected four distinct 4T1 clones - F, G, J, and T - based on their transcriptomic
di erences (Wagenblast et al., 2015). The four clones were most transcriptomically
diverse and thus, should capture the full transcriptomic range allowing us to establish
our CloneSTAR system in the context of the 4T1 model. Besides establishing Clon-
eSTAR barcode detection, we also used the system to test whether we could define
specific gene expression patterns to identify clones as an alternative approach.
We infected each of the clones with a unique CloneSTAR barcode - F clone with
BC2, G clone with BC3, J clone with BC4 and T clone with BC5 - and sorted based
on the zsGreen expression. To test whether we can detect individual clones, we applied
CloneSTAR to a mixed population of all clones (Figure 4.2b). Briefly, cells were
plated in equal ratios as a mixture into Bind-Silane coated 24-well plates and grown
for 48 hrs prior to fixation. We performed the STARmap protocol using SNAIL probes
designed to target either a constant region in the CloneSTAR transcript constant
across barcodes allowing to visualize all cells expressing our barcode transcript, or a
specific SNAIL probe pair against each CloneSTAR barcode. We further included a
condition for each clone-probe pair, where we omitted the corresponding clone to rule
out cross-reactivity and check for specificity of our SNAIL probes.
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Figure 4.2 CloneSTAR barcode design and testing barcode detection in vitro in
4T1 clones - F, G, J, and T. a | Schematic illustration of CloneSTAR vector. The 40mer
CloneSTAR barcode, which consists of two 20mer cassettes separated by one nucleotide was
cloned into the pHSW8 vector backbone. b | Testing barcode detection in 4T1 clones F, G,
J, T. In a 24-well plate, cell clones were plated and cultured together. After two days, cells
were fixed and CloneSTAR barcodes were detected using STARmap. A control condition
was included for each clone-probe pair where the concatenated clone was omitted to rule out
cross-reactivity of our SNAIL probes. All four barcodes were detected and no cross-reactivity
between barcodes was observed. Probes targeting zsGreen visualised all BC expressing clones
independent of their barcode sequence. Scale bar represents 50 µm.
We found that the CloneSTAR barcode transcript was detectable in the majority
cells when using a single probe targeting a constant region of the barcode transcription.
We observed various expression levels of CloneSTAR transcripts between clones. More-
over, we were able to identify the di erent clones based on barcode detection without
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observing any cross-reactivity between barcode and probe pairs using our CloneSTAR
technology.
4.3.2 Visualising di erential gene expression profiles of clones
with STARmap
To define marker genes specific for each clone, we analysed scRNA-seq data derived
from a mixed population of the four clones (Figure 4.3a). CloneSTAR barcodes are
expressed and readily captured within each single-cell transcriptome, enabling clonal
identification. We assigned clusters to the individual clones (F, G, J and T) based on
their barcode expression (Figure4.3b).
As expected, cultured cells clustered based on their clonality. Consistent with our
prior CloneSTAR experiment, we observed variable levels of barcode expression and/or
detection between the clones (Figure 4.3b) with highest expression being detected
in the T clone (31.7%), F (34.7%) and J clone clusters (30.1%), while the G clone
cluster showed the lowest barcode expression (10.5% barcodes). Overall, barcodes
were assigned to 23.7% of the cells. Using the assigned clusters, we selected specific
marker genes for each clone. We defined genes significantly enriched per cluster and
selected specific markers for each clone based on the following criteria: Genes (1)
significantly enriched in clusters of clone of interest, (2) not significantly enriched
in any other cluster, and with (3) a log-fold change > 0.3 between clusters of clone
of interest and the rest. From the genes matching these criteria we selected a final
list of clonal markers, which defined gene expression signatures specific to each clone,
consisting of 16 genes (Figure 4.3c) and four clonal barcodes. We further included
four genes (Rack1, Hsp90b1, Eif2f and Cdk4) universally expressed across all clones
and not significantly enriched in any clone.
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Figure 4.3 ScRNA-seq of CloneSTAR labelled 4T1 cells in vitro and selection of
clonal markers. UMAP representation of CloneSTAR scRNA-seq dataset highlighting the
di erent clusters (a) and the expression of the CloneSTAR barcode transcripts (b). c| Gene
expression heatmap representation of markers for each clone. Genes shown were selected
based on only being significantly enriched in the cluster of interest and not in any other
cluster with a logFC > 0.3. Rack1, Hsp90b1, Eif2f and Cdk4 were selected as universally
expressed genes present in more than 70% of the cells and not significantly enriched in any
cluster.
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To investigate whether the gene expression correlated with the barcode expression,
we generated a probe library of the 16 clonal marker genes and four CloneSTAR
barcodes and performed CloneSTAR (Figure 4.4).
Figure 4.4 Detection of 16-gene library and CloneSTAR barcodes in vitro. Fluo-
rescent images of STARmap across all six cycles. All four clones were plated in a mixture
and full six cycles of STARmap were applied using a 16 gene library with clonal marker
genes. Barcodes were detected with single probes at the end as well as through SEDAL.
Gene transcripts were read out over five cycles using SEDAL. Scale bar represents 50 µm.
Following the five readout cycles in three channels to detect the 16-gene library,
CloneSTAR barcodes were visualised with single probes. The identify of each RNA
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species is encoded as a five-base barcode manifested in the DNA amplicon and read out
through several cycles of hybridisation - ligation - imaging - stripping. Ligation of read-
ing and decoding probes only takes place if both probes are perfectly complementary
to the DNA template resulting in a stable product, allowing unligated probes to be
washed away. After each imaging cycle, probes are stripped from the tissue-hydrogel
for the next cycle to begin. In contrast to the original STARmap protocol, we only
used three channels (546, 594, 647) due to high background fluorescence in channel 488.
To align the images acquired in di erent cycles and for cell segmentation, we stained
the nuclei with DAPI.
We are currently optimising the analysis pipeline in order to decode the gene
expression across the five cycles (Figure 4.5c). Nonetheless, we clearly demonstrated
that we can do multiple cycles of hybridizing and stripping without any bleed-through
from previous rounds or between channels. To detect 16 genes plus four barcodes
in three colours, seven rounds would have been necessary using a standard smFISH
scaling linearly. In contrast, CloneSTAR only requires three rounds to readout 27
genes of interest with no redundancy. Our current approach, using three channels
and five cycles, has the potential to measure the gene expression of 240 genes of
interest. Notably, we did not observe an appreciable decrease in signal through the
cycles. Preliminary analysis revealed distinct expression of genes in di erent clones, as
expected. For example, T clone markers, all encoded in channel 546 in cycle 1, nicely
aligned with the barcode expression (Figure 4.5). This o ers the potential of using
pre-defined gene expression signatures to identify clones in a spatial context.
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Figure 4.5 CloneSTAR barcode detection aligns with clonal marker genes in vitro.
a| Image shows barcode detection highlighting clonal populations. b| T clone marker gene
expression (Gchfr, Polr2f, Vim, Gcat, Mt2 and BC5) in the first cycle of 16-gene set library
in the 546 channel. T clone barcode expression aligns with expression of markers genes. Scale
bar represents 50 µm. c| Code book for 16-gene library and barcodes. Colours highlight the
di erent channels: 546 = magenta, 594 = cyan and 647 = yellow.
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4.3.3 Establishing STARmap in breast cancer tissue
We next wished to establish the protocol in vivo in 4T1 breast cancer tumours. Tumours
harbour a highly heterogeneous tumour microenvironment with complex, spatially
restricted interactions with the immune system. Cells of the tumour microenvironment
have been extensively studied using scRNA-seq and in situ hybridisation, yielding
well-defined transcriptional markers to identify cellular identities (Figure 4.6a).
84 CloneSTAR: Visualising clonal populations in space
Figure 4.6 Selection of tumour microenvironment markers. a| UMAP representation
of 4T1 tumour scRNA-seq dataset highlighted by cell phenotype. b| Gene expression heatmap
representation of key marker genes used to identify cells of the tumour microenvironment.
EC=Endothelial cells, FB=Fibroblasts, NK=Natural killer cells, TC=T-cells.
To this end, we performed scRNA-seq of our 4T1 breast tumours and compared
lineage marker expression in order to assign cell identities in 4T1 breast tumours.
The resulting cell phenotypes fell broadly into the categories of tumor, stroma and
immune cells. We selected specific markers for T-cells, macrophages, endothelial cells,
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fibroblasts as well as tumour cells (Figure 4.6b) and also included markers for hypoxia,
which is a prominent feature in 4T1 tumours.
Table 4.2 Tissue pre-treatment conditions tested on 4T1 breast tumour tissue
Name Step1 Step2 Step3
None 100% Methanol for 10 mins at
-20 ¶C and 15 mins at -80 ¶C
None None
SDS 100% Methanol for 10 mins at
-20 ¶C and 15 mins at -80 ¶C
None 4% SDS in PBS for 2
mins at RT
Short Pepsin 100% Methanol for 10 mins at
-20 ¶C and 15 mins at -80 ¶C
None 1 mg/ml pepsin in
0.1N HCl for 10 mins
at RT
Long Pepsin 100% Methanol for 10 mins at
-20 ¶C and 15 mins at -80 ¶C
None 1 mg/ml pepsin in
0.1N HCl for 30 mins
at RT
Low Prot K 100% Methanol for 10 mins at
-20 ¶C and 15 mins at -80 ¶C
None 1 µg/ml proteinase
K in 1XPBS for 10
mins at RT
High Prot K 100% Methanol for 10 mins at
-20 ¶C and 15 mins at -80 ¶C
None 20 µg/ml proteinase
K in 1XPBS for 10
mins at 37 ¶C
Triton +
SDS
100% Methanol for 10 mins at
-20 ¶C and 15 mins at -80 ¶C
0.5% Triton
for 15 mins
4% SDS in 1XPBS
for 2 mins at RT
Ethanol +
Triton
70% Ethanol for 10 mins at







70% Ethanol for 10 mins at
RT and 1 hr at 4 ¶C
0.5% Triton
for 15 mins
4% SDS in 1XPBS
for 2 mins at RT
To test the resulting 24-gene set library on tumour tissues using STARmap, we
collected fresh frozen 4T1 tumours sections onto treated glass-slides or into wells of
a 24-well chamber. Breast tumours are though tumours with a high percentage of
fat and connective tissue which represents a challenge for tissue clearing techniques.
Therefore, we optimized the original STARmap protocol and included a pre-treatment
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step. We tested various pre-treatment conditions (Table 4.2) and found that using
4% SDS in 1XPBS was most e ective in preserving the detection signal.
Following the initial clearing process using 4% SDS in 1XPBS, we applied the
STARmap protocol and decoded the gene-specific identifiers over 5 cycles. Nuclei
were stained with DAPI for cell segmentation and image alignment. We specifically
designed our probe set such that all markers for a specific cell type could be identified
unambiguously in at least one of the sequencing cycles (Figure 4.7b). For example,
channel 546 showed all T-cell markers in cycle 1 while all macrophage markers were
visualised in cycle 2. We are currently still optimizing the analysis in order to decode
the full geneset.
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Figure 4.7 Identification of cell types in vivo using STARmap a| Visualisation of the
tumour microenvironment in 4T1 tumours. Nuclei were stained with DAPI and cell type
identification was performed using a 24-gene set library and STARmap. Scale bar represents
50 µm.b| In situ encoding scheme. Magenta=Alexa547, Cyan=Alexa594, Yellow=647.
4.3.4 Visualisation of clones in vivo
In order to test whether we can identify clones in vivo using the CloneSTAR barcode,
we generated a tumour by pooling the four 4T1 CloneSTAR clones at equal ratios and
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transplanting 60,000 cells bilaterally into the mammary fat-pad of a Balb/C mouse.
To confirm for the expression of the transcriptional signatures of the clones in vivo,
we performed scRNA-seq on one of the tumours and processed the other tumour for
downstream analysis with the CloneSTAR protocol.
Figure 4.8 CloneSTAR barcode detection in vivo using scRNA-seq and STARmap.
a| UMAP representation of CloneSTAR tumour cluster highlighting the di erent clones. 4T1
clones F (BC2), G (BC3), J (BC4) and T (BC5) were pooled at equal ratios and 60,000 cells
were transplanted on both sides into the mammary fat-pad of a Balb/C mouse. Tumours were
collected after 21 days and split between scRNA-seq and CloneSTAR analysis. ScRNA-seq
revealed that tumour was mostly dominated by the T clone, while only a few other clones were
detected. b Spatial distribution of CloneSTAR clones injected into the mammary fat-pad of
a Balb/C animal. Tumours were collected after 21 days and fresh frozen.
Analysis of the scRNA-seq data revealed that the majority of the tumour consisted
of the 4T1-T clone (Figure 4.8a). Overall, the CloneSTAR barcode transcript was
detected in 57% of all tumour cells with the T clone alone accounting for 56% of
barcode assignment. We observed seven barcodes of the F clone, six for the G clone
and only one for the J clone. Based on the low expression of most barcodes in our
CloneSTAR tumour, we decided to target a common region of the barcode transcript
first to increase our chances of detecting the RNA. We used two probes targeting the
3’UTR of zsGreen in the CloneSTAR vector (Figure 4.8b). Although we observed
specific signal in the tumour sample, the expression was very low indicated by the
low number of spots in relation to the amount of cells detected with the nuclear stain
and was further highly dependent on the area visualised. The low number of detected
4.3 Results 89
transcripts could be due to the low expression of the CloneSTAR barcode or sterical
hindrance which blocks SNAIL probes from binding.
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4.4 Discussion
Single-cell RNA sequencing (scRNA-seq) characterises the transcriptome of individual
cells and has the power to reveal rare subpopulation within a given tissue. However,
this comes at the cost of spatial information and thus, limiting our understanding of
intercellular communication and organisation in the tumor microenvironment. Using
a spatial transcriptomic approach to interrogate a tissue meets this challenge by
measuring genes expression of pre-selected markers with detailed positional information
in an intact tissue.
To bridge this gap, we developed CloneSTAR, an integrative approach of scRNA-seq
and STARmap to study transcriptionally characterised clones within their native tissue
context. The method begins with marker characterisation of cells types and clonal
populations present in a tissue by scRNA-seq, followed by identification of niches
enriched for distinct transcriptomic signatures using spatial transcriptomics and the
pre-defined markers from the sequencing analysis. We adapted our WILDseq approach
(presented in Chapter 2&3) and generated a novel expressed barcoding system allowing
the detection of clonal barcodes with STARmap. Our results demonstrated the power
of CloneSTAR in detecting di erent clones in vitro using four transcriptionally distinct
clones of our 4T1 mouse model. First, we showcased that we can robustly identify
di erent clones in a mixed population of cells in culture. Secondly, transcriptomic
characterisation of the clones confirmed distinct expression signatures and allowed the
selection of clonal marker genes. Our CloneSTAR results showed that clonal identities
aligned with gene expression signatures in vitro.
The widest application of spatial transcriptomic approaches has been to study
the tumour microenvironment. To this end, we successfully established STARmap
in vivo in targeting the tumour microenvironment in 4T1 breast tumours. Based on
the low number of barcode assignments in the scRNA-seq in vitro data, which has a
higher sensitivity than CloneSTAR, we anticipated that detection of barcode in vivo
using CloneSTAR will be challenging. The signal was weak in the dense tumour tissue
and we only observed a low number of detected transcripts. Future studies will focus
on improving barcode detection by using a stronger promoter to increase barcode
expression or using padlock probes instead of SNAIL probes requiring only one probe
to bind instead of two. Alternatively, we will explore the possibility to detect genetic
clonality using DNAFISH or transcription sites to detect clones in vivo. Furthermore,
distinct gene expression patterns of clones might also allow clonal identification. Our
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preliminary results revealed specific alignment of distinct gene expression patterns and
clonal identities in vitro. It will be interesting to test the transcriptomics signatures
in vivo as an alternative approach to identify clones. To this end, the multiplexing
capacity of STARmap represents a key feature allowing us to encode enough genes to
identify clones in vivo. CloneSTAR has the potential to provide a new perspective into
the organisation of distinct clonal populations and their interactions in local tissue




Molecular di erences between individual cells can translate into marked di erences
in cell fate, especially in determining survival versus death of tumour cells during
therapeutic intervention. Identifying the origin of these di erences remains a challenge
due to the hidden nature of the molecular causes that lead to a distinct cellular fate in
bulk data. Single-cell RNA sequencing methods have emerged as a powerful tool to
resolve this underlying tumour heterogeneity and provided insights into phenotypes of
stromal and tumour cells in di erent cancers. Triple-negative breast cancer (TNBC) is a
highly heterogeneous and aggressive disease that frequently develops therapy resistance.
An unresolved question is what precisely distinguishes distinct cellular outcomes to
treatment and can we predict cellular fate based on di erences in the initial states
of cells. Resistance might be caused by the selection of rare pre-existing clones or
alternatively through the adaptation of clonal intrinsic and extrinsic processes. The
aim of this thesis was to uncover functionally heterogeneous subpopulations of tumour
cells with di erent treatment sensitivity and understand how clonal lineage-dependent
transcriptomic diversity contributes to these phenotypes.
Here we developed WILDseq (Wholistic Interrogation of Lineage Dynamics by
sequencing), a high-complexity expressed barcode library for simultaneous mapping
of each cells’ clonal identity and transcriptional states. The barcode is constitutively
expressed within the 3’ untranslated region of a polyadenylated zsGreen transcript,
enabling sequencing via standard oligo dT-capturing chemistry. To mine tumour
heterogeneity and couple it to scRNA-seq, we created and optimized a bottlenecking
strategy enabling the identification of the appropriate pool size of labelled cells. This
step is crucial for the success of the method - too large a starting population of cells
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and the number of founding clones/barcodes will be too large to generate su cient data
on an individual clone, too small a starting population and it will lack the diversity
required to capture phenotypic variation. We generated our WILDseq pool from 750
barcoded cells which resulted in the detection of 132 clones in vitro after stabilisation
in culture.
We applied WILDseq to a syngeneic mouse model of breast cancer yielding 64,000
single-cell profiles and 69 distinct clones, indicating that over 50 % of all injected clones
successfully survived and expanded. When we compared transcriptional signatures for
the most abundant clones in vivo versus in vitro we observed only a weak correlation
indicating that clonal gene expression mostly depends on external factors, such as
tumour microenvironment or growth factor supply.
Non-genetic mechanisms, such as transcriptional and epigenetic changes, have
recently emerged as important drivers of drug resistance in cancer (Salgia and Kulkarni,
2018). Our results revealed two di erent mechanisms of treatment resistance. The
gene signatures associated with chemoresistance included hypoxia and EMT, the latter
relating to the transition of tumour cells to mesenchymal phenotypes in response to
cytotoxic therapy. This observation has previously been reported in several studies
performed in post treatment samples from breast cancer patients (Almendro et al.,
2014; Kim et al., 2018). Similarly, hypoxia has been shown to enhance chemoresistance
in tumour cells via HIF-1 (Doktorova et al., 2015; Petit et al., 2016). Our results
are consistent with a previous study in TNBC patients that reported that a small
subpopulation of tumour cells were primed through their transcriptional programs for
a resistant phenotype (Kim et al., 2018). Future work will focus on functional studies
to validate our chemoresistant gene signatures and understand their mechanistic roles
in conferring resistant phenotypes. Using the CRISPR-Cas9 toolkit, we will induce
loss of function mutations in target genes reversing therapy resistance. Alternatively,
we will overexpress candidate genes and thereby, reinstating a chemoresistant pheno-
type in chemosensistive cells. Moreover, our data o ers the possibility to overcome
chemoresistance by using a combination therapy with inhibiting hypoxia through HIF-1
inhibitors (Hu et al., 2013) or targeting EMT signaling to re-sensitise tumours cells to
chemotherapy (Marcucci et al., 2016).
BET bromodomain inhibition has demonstrated e cacy in triple-negative breast
cancer (TNBC) and other cancer types, but inherent and acquired resistance limit
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their potential use in the clinic. We leveraged our WILDseq platform to explore the
clonal drug response to the BET bromodomain inhibitor JQ1. Our results revealed a
cell state that intrinsically primed tumour cells to be sensitive to JQ1 treatment, while
JQ1 resistance was mediated through external factors. Sensitive cells exhibited high
levels of DNA damage repair (DDR)-related gene sets at baseline. Previous studies
have shown that DNA damage induced a p53-mediated reduction of MYC expression
(Porter et al., 2017). JQ1 has been reported to downregulate MYC transcription,
followed by global suppression of MYC -dependent target genes (Delmore et al., 2011).
Thus, the combined e ect of MYC suppression resulted in a dramatic decrease of
MYC in JQ1-sensitive cells. While JQ1-sensitivity was primed through an intrinsic
cell state, JQ1-resistance was mediated by micro-environmental factors. We found a
global downregulation of gene sets involved in antigen presentation accompanied with
a specific depletion of CD8+ T-cells resulting in an immune "cold" tumour. Clonal
populations with higher levels of antigen representation via MHC class I showed high
abundance in vitro, but were only able to survive and expand in the presence of JQ1
treatment. Our data contrast with previous studies that reported the suppression of
PD-L1 expression by BET bromodomain inhibition resulting in an increase in the
activity of anti-tumor cytotoxic T cells (Hogg et al., 2017; Zhu et al., 2016). One of the
studies further demonstrated a synergistic response of JQ1 and immunotherapy with
anti-PD1 in a Myc-driven lymphoma model (Hogg et al., 2017). Future experiments
are required to confirm our hypothesis, starting with analysing the clonal distribution
of our WILDseq pool in an immunocompromised animal. Alternatively, we will test
whether overexpression of Myc can rescue JQ1-sensitive cells.
Further use of integrative tools like WILDseq, in combination with in situ sequenc-
ing approaches, may help to fully reveal the tumour and its surrounding landscape
and directly map clonal transcriptomic di erences to their causality. Thus, we aimed
to develop a version of WILDseq compatible with the spatial transcriptomics method
STARmap. Our resulting CloneSTAR approach has the ability to visualise clonal
subpopulations in vitro combined with measuring gene expression in a spatial con-
text. We leveraged the expressible nature of the barcode to first perform a detailed
transcriptomic characterisation of our clones in order to map and align transcriptomic
profiles and clonal identities. Furthermore, we successfully implemented STARmap
on breast cancer tissue. However, identification of clones in vivo through detection of
the CloneSTAR barcode will require further optimisation. In future work, exchang-
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ing the promoter to enhance expression or generating a longer barcode to have more
sequencing space may improve this technique in order to be utilised in an in vivo setting.
Overall, our data have several important clinical implications. First, the pre-
existence of chemoresistant phenotypes in the tumour mass indicates that there might
be diagnostic possibilities for detecting biomarkers for resistance and sensitivity in
patients prior to treatment allowing to anticipate treatment benefits. Second, we found
a novel resistance mechanism to BET inhibition demonstrating the importance of
having a functional host immune system present. This is a key advantage of WILDseq
over CRISPR-Cas9 lineage tracing approaches that rely on the delivery of multiple
components resulting in an increased risk of immunogeneicity and vector silencing.
Due to its compatibility with syngeneic models, WILDseq would be well suited to
study clonal response to immunotherapy and increase our understanding of therapy
response and resistance to immunotherapy. Third, integrating transcriptional profiles
and clonal identities with the spatial information has the potential to directly map
clonal transcriptomic di erences to their causality completing the picture of the tumour
and its surrounding landscape.
Overall, we have developed a novel integrative platform, called WILDseq, that can
enable high-resolution mapping of clonal identities and cell states. This technology
will increase our knowledge about how complex and heterogeneous tumour popula-
tions change and adapt to perturbations such as drug treatment, providing a novel
and valuable tool for the study of tumour heterogeneity and evolution. Ultimately,
understanding (epi)genomic, transcriptomic, and phenotypic changes that occur during
tumour evolution upon therapeutic intervention may inform treatment strategies and
lead to better clinical outcomes.
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